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The cellular FLICE-like inhibitory protein (cFLIP) is well known as a major 
immunomodulatory protein. Various works have described its role in major cellular 
pathways such as apoptosis, autophagy, necroptosis, NF-kB regulation and more 
recently, modulation of interferon responses. Interferon a (IFNa) and interferon b (IFNb) 
are in the class of type I IFN and are critical as the first line of defense against viral 
infection. Interestingly, these IFNs also maintain roles apart from viral infection 
including participating in the pathophysiology of tumor biology and autoimmunity.    
Previous studies found that cFLIPL could inhibit IFNb production. My work 
demonstrated that this was by inhibiting the major transcription factor for IFNb 
expression, interferon regulatory factor 3 (IRF3). Mutational analysis revealed that the 
CLD within the C-terminus of cFLIPL is responsible for inhibiting IRF3-CBP-DNA 
interactions. Further, when cFLIPL was knocked down in various tumor cell lines, levels 
of tumor protective interferon stimulated genes (ISGs) increased, suggesting cFLIPL may 
contribute to tumorigenesis by way of inhibiting IRF3.  
In addition, cFLIPL also inhibited IFNa production by inhibiting the transcription 
factor, IRF7. In this case, the CLD of cFLIPL was dispensable to inhibit 
IFNa production; an alternative shorter isoform, cFLIPS, which lacks the CLD, also 
inhibited IRF7-induced IFNa expression. IRF7 phosphorylation was greatly reduced in 
cells expressing cFLIPL and cFLIPS. I hypothesized cFLIP targeted the IKKa kinase. In 
support of this hypothesis, I found that cFLIPL co-IPs with IKKa and IKKa-IRF7 
interactions were disrupted in the presence of cFLIPL. These interactions were confirmed 
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in a pDC-like cell line overexpressing cFLIP, suggesting that the mechanism by which 
cFLIP inhibits IFNa production is physiologically relevant.  
Taken together, these data suggest that cFLIP is a major regulator of type I IFNs. 
It is of major clinical interest to regard the regulation of type I IFN expression by cFLIP 
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Chapter 1: Introduction to the thesis 
 
1.1  The Importance of Type I Interferon Production in Innate Immunity  
Overview  
Production of interferon (IFN) is well-known as the “first line of defense” against 
viral infection. With its discovery in 1957 by Drs. Alick Isaacs and Jean Lindenmann, the 
concept of antiviral immunity was forever changed (43, 47). The ongoing investigations 
in the fields of viral immunity and IFNs have led to rapid growth in the knowledge of the 
various immunological functions of IFNs. Interestingly, IFNs play many more roles than 
just preventing viral spread, and are now appreciated as participating in tumor control. 
However, IFNs also contribute to autoimmune pathologies (21, 24, 110). The benefit of 
IFN production compared with this negative consequence is completely dependent on 
how IFN expression is regulated (96). This thesis will describe two mechanisms by which 
a particular cellular protein, cellular FLICE inhibitory protein (cFLIP), regulates IFN 
production.  
Classes  
IFNs are signaling proteins that are produced in response to various pathogens or 
stimuli. There are three classes, or types, of IFN including type I (the class majorly 
involved in the antiviral response), type II (this class includes IFNg produced by type 1 T 
helper cells in response to IL-12), and type III (more recently discovered, but also plays a 
distinct role in certain viral infections) (54, 89). The major class, type I, consists of IFNa, 
IFNb, IFNk, and IFNw, and the best-defined IFNs are IFNa, and IFNb (44). Type I IFN, 
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their regulation of production, and their physiological and clinical importance will be the 
major subjects of this thesis.  
Production and signaling  
While most cells produce IFNb, IFNa is produced mainly by hematopoietic cells, 
such as plasmacytoid dendritic cells (pDCs) (44). Production of type I IFN occurs via 
triggering of pattern recognition receptors (PRRs) within the cell and/or by 
autocrine/paracrine signaling via the IFNa/b receptor alpha chain (IFNAR). IFNb is 
mainly produced in response to double stranded (ds) and single stranded (ss) RNA 
produced by virus infection. These byproducts activate the pattern recognition receptors 
(PRRs), retinoic acid inducible gene I (RIG-I) and melanoma differentiation-associated 
protein 5 (MDA-5). Activation of these proteins engages the mitochondrial antiviral-
signaling protein (MAVS) which further results in phosphorylation and activation of the 
kinases TANK binding kinase 1 (TBK1) and I-kappa-B kinase epsilon (IKKe). The 
TBK1:IKKe heterodimer phosphorylates the key transcription factor, interferon 
regulatory factor 3 (IRF3). IRF3 homodimerizes, translocates to the nucleus, and drives 
transcription of IFNb, as well as other ISGs (Figure 1.1) (Paulden et al., 2013; 31; 45).  
In contrast, IFNa is produced in response to unmethylated RNAs from pathogens 
and damaged host cells as well as unmethylated CpG DNA complexes (52). These 
pathogen associated molecular patterns (PAMPs) bind to and activate toll-like receptor 
(TLR) 7/8 and TLR9 within endosomes of the host cell (1, 52). The major adaptor 
proteins in this pathway include MyD88 which complexes at the endosome with other 
key players including TNF-receptor associated factor 6 (TRAF6), a ubiquitin ligase, 
interleukin 1 and 4 receptor associated kinases (IRAK1/4), I-kappa-B kinase alpha 
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(IKKa), and the key transcription factor, interferon regulatory factor 7 (IRF7). Similar to 
IRF3, IRF7 will homodimerize, translocate to the nucleus and drive transcription of 
IFNa, and other ISGs (Figure 1.1) (36, 49) (Figure 1.1).  
In the canonical pathway of interferon signaling, newly synthesized IFNa/b will 
bind to cell surface receptor, IFNAR. The activation of this receptor leads to the 
activation of the janus kinase/signal transducer and activator of transcription 
(JAK/STAT) pathway where, upon engagement, STAT1/STAT2 will assemble with 
interferon regulatory factor 9 (IRF9) to form a complex termed IFN stimulated gene 
factor 3 (ISGF3). This complex will translocate to the nucleus to bind to its target DNA 
sequence and drive the transcription of several hundred interferon stimulated genes 
(ISGs) (Figure 1.2) (57, 92) (Figure 1.2).  
Mechanisms of specificity for ISG control  
A common misconception of type I IFN is that they act directly on the pathogen 
that activated their production. In fact, they are simply the crucial messengers that lead to 
viral defense via up regulation of transcription of hundreds of interferon-stimulated genes 
(ISGs). The different type I IFN subtypes (including 14 IFNa subtypes, IFNa1-IFNa14, 
and IFNb) each specifically regulate different ISGs, providing a means to provide diverse 
ISG expression in a precise way (27, 82). For example, infection by influenza virus will 
yield a different repertoire of ISGs as compared to hepatitis C virus infection. The exact 
mechanism for how each type I IFN subtype controls specific ISG production is not well 
understood, and may be based on affinity of different IFN molecules with their receptor.   
Despite the extensive number of ISGs known, there are a few ISGs that are 
commonly up regulated during viral infection by a diverse set of viruses. These include 
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previously mentioned immune genes such as ddx58 (encoding RIG-I) ifih1 (encoding 
MDA-5), irf3, ifr7, irf9, as well as genes encoding proteins with direct antiviral activity 
like myxovirus resistance proteins (MxA and MxB), interferon stimulated gene 15 
(ISG15), interferon stimulated gene 54 (ISG54), and oligoadenylate synthase-like protein 
(OASL) (61, 101). MxA and MxB proteins elicit an antiviral response by targeting whole 
viruses or viral proteins for degradation (61, 97). ISG15 promotes ISGylation of 
mitochondrial proteins similar to ubiquitination to target proteins for signal transduction 
or degradation (69). ISG54 promotes cell death of virus-infected cells by activating 
intrinsic apoptosis dependent on Bcl-2 (79). OASL functions by activating the 
endoribonuclease, RNaseL, leading to degradation of cellular and viral mRNAs with the 
end goal of limiting viral replication (19). Altogether, the various biological functions 
elicited by each ISG combine to produce a successful defense against viral infection.  
In the context of tumor biology, type I IFN control of ISGs is another complex but 
widely studied topic. Simply put, the downstream effects of IFNs and ISGs on the tumor 
microenvironment is highly dependent on concentration and time. For example, long-
term expression of endogenous concentrations of IFNs can have more of a pro-tumor 
effect while anti-tumor related ISGs will be expressed in response to high doses of IFNs 
for shorter times (18). When endogenous levels of IFN are upregulated, such as is the 
case during oncovirus infection or exposure to DNA damaging agents (17, 107), an 
upregulation of ISGs such as IFI27 (involved in promoting cytochrome C release), ISG15 
(involved in ISGylation), and BST2 (indirectly involved in inhibiting cell growth and 
migration) is observed (16). A further upregulation of ISGs involved in promoting 
apoptosis and antagonizing proliferation are not observed during increased endogenous 
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exposure to type I IFN, potentiating the protumor effect (56). Conversely, at high doses 
of exogenous IFN, the induction of pro-apoptotic ISGs such as TRAIL, OAS, PKR, and 
several other proteins can establish an anti-tumor microenvironment. ISGs that inhibit 
angiogenesis, like guanylate binding protein (GBPs) and promyelocytic leukemia gene 
(PML) are also upregulated in response to high doses of type I IFN, contributing to tumor 
protection (93, 99). In summary, the ISG signature observed in healthy vs. cancer patients 
is remarkably different. Therefore, promoting or blocking IFN driven ISG expression can 
be a useful therapeutic tool when considering tumor biology.  
Another pathological state involving type I IFN driven ISG expression includes 
autoimmunity. One particular example of an autoimmune disorder strongly implicating 
IFN is systemic lupus erythematosus (SLE). The investigation into the mechanism 
driving IFN stimulated autoimmunity began after clinicians had started treating cancer 
patients with exogenous IFNa  and noticing autoimmune-like phenotypes (83). This 
further led to the discovery that many patients with already known autoimmune disorders 
had an apparent IFN signature, suggesting IFN and ISGs are major contributors to the 
disease pathology (8). For example, an increase in IFNa-induced OASL and MxA can be 
seen in a majority of SLE patients (76, 102). The main cell type involved in this 
upregulation includes activated plasmacytoid dendritic cells (pDCs); they are the major 
producers of IFNa within the host. By a mechanism still not fully understood, patients 
with SLE with have low circulating levels of pDCs because these cells have migrated to 
various tissues where they are producing high levels of IFNa and ISGs that contribute to 
tissue damage (83). Further, IFNa activates various immune cells to release 
autoantibodies. The IFN cycle continues, establishing an autoimmune state. Targeting 
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and suppressing IFNa production in SLE patients is therefore a major field of 
investigation. 
Regulation  
Regulatory control of IFN production is critical because of the strong effects of 
IFN. This balance must be maintained when considering immunosuppression (animals 
lacking IFN production will be much more susceptible to pathogens), and when 
considering autoimmunity (high levels of IFN production, namely IFNa, is highly 
correlated to some autoimmune disorders). Therefore, the host cell must possess 
mechanisms to precisely turn on or off IFN production temporally. This balance is 
controlled by host cell regulatory proteins. Conversely, pathogens have adapted to 
combat host cell defenses. Here, I will be discussing major cellular regulatory proteins as 
well as pathogen-encoded immunomodulatory proteins that are involved in regulating 
type I IFN production.  
Cellular regulatory proteins  
Healthy cells must downregulate or prevent type I IFN production. Several 
cellular proteins are known to inhibit type I IFN by sequestering IRF3 and IRF7 through 
common mechanisms such as directly or indirectly targeting proteins for degradation, 
inhibiting their transcription, and dephosphorylating important signaling molecules. 
Some representatives of regulatory proteins that utilize these mechanisms include PP2A 
and RACK1, FoxO3 and FoxO1, TRIM26, RBCK1, and RAUL (Figure 1.3). 
As previously mentioned, IRF3 must be phosphorylated to be activated. 
Therefore, it makes sense that there are regulatory proteins that shut down IRF3 
activation by dephosphorylating IRF3 when it is no longer needed. The protein 
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phosphatase (PP2A) depends on the adapter protein, receptor for activated C-kinase 
(RACK1) to form a complex and dephosphorylate IRF3 within the cytoplasm. In 
previous studies, knockdown of PP2A resulted in enhanced type I IFN production and 
protection against SeV and VSV infection in mice (63).  
Another regulatory mechanism to limit type I IFN production includes controlling 
transcription IRF3 or IRF7. Forkhead box protein O3 (FoxO3) was identified to inhibit 
IRF7 transcription within the nucleus (60). Therefore, decreased IRF7 transcription in 
turn leads to decreased IFNa production. While dephosophorylation and transcriptional 
regulation are effective mechanisms to limit type I IFN, the most popular mechanism 
seems to be degradation of important adaptor proteins in the IFN pathway. Interestingly, 
this thesis will later describe the  
cellular protein, cFLIP, as a regulatory protein of type I IFN that does not use any of 
these common mechanisms.  
Regulatory proteins that use degradation mechanisms can do so either directly or 
indirectly. For example, FoxO1, a close family member to FoxO3 previously mentioned, 
acts as a negative regulator of IRF3 by associating with IRF3. This complex then 
indirectly promotes K48-linked ubiquitination by an unknown ubiquitin (Ub) ligase (55). 
On the other hand, regulators of IFN production can themselves be direct Ub ligases.  
Tripartite motif-containing protein 26 (TRIM26), RBCC protein interacting with 
PKC1 (RBCK1) and RTA-associated ubiquitin ligase (RAUL) are examples of ubiquitin 
(Ub) ligases that act by directly polyubiquitinating their target proteins, leading to 
degradation by the proteasome. TRIM26 has been shown to lead to IRF3 and IRF7 
degradation while RBCK1 acts only on IRF3 (100, 108). Therefore, if the cell wants to 
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downregulate both IFNb and IFNa response, it may activate TRIM26 more so than 
RBCK1, whose effects result in suppressing IFNb production. RAUL is an Ub ligase that 
was originally identified as a target of the Kaposi sarcoma-associated virus (KSHV) E3 
ligase, RTA. RTA association with RAUL led to IRF3 and IRF7 degradation (105). 
Then, Yu et al. discovered that RAUL was a cellular regulatory factor being exploited by 
KSHV to dampen type IFN response by leading to IRF3 and IRF7 degradation (106). 
This exemplifies how pathogens have evolved to counter our immune responses. The 
next section describes relevant viral-encoded immunomodulatory genes. 
Viral immunomodulatory proteins that suppress type I IFN effects  
Very well studied viral-encoded proteins that target and suppress type I IFN 
production or signaling arising from IFNIFNAR interactions include the influenza A 
virus (IAV) NS1 protein; the molluscum contagiosum virus (MCV) proteins MC159 and 
MC160; the KSHV proteins K13 and RTA (as previously mentioned); and the NSP1 
rotavirus protein (Figure 1.4). While this list is not complete, I discuss these proteins 
because they are well characterized in the context of type I IFN regulation and focus on 
the same signal transduction pathways that cFLIP targets.   
  The nonstructural protein 1 (NS1) protein of IAV inhibits type I IFN production 
by two mechanisms. First, it inhibits IRF3 activation by sequestering TRIM25, which is 
the protein responsible for activating the RIG-I CARD domain (25). Second, the NS1 
protein inhibits processing of IFN pre-mRNAs (53).  
The rotavirus nonstructural protein 1 (NSP1), like most cell regulatory factors, 
inhibits type I IFN by inducing proteosomal degradation of transcription factors IRF3, 
IRF5 and IRF7 (3). Interestingly, it also targets IRF9 for proteosomal degradation, 
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abrogating the ISGF3 complex and downstream JAK/STAT signaling, resulting in even 
stronger suppression of host cell IFN responses (2). 
A family of proteins called FLICE inhibitory proteins (FLIPs), which will be 
discussed thoroughly within the next sections, are both cellularly and virally-encoded. 
Three well-studied viral FLIPs include the MCV MC159 and MC160 and the KSHV K13 
proteins. In a study conducted by Randall et al., these FLIPs inhibited IRF3 activation. 
MC159 binds to kinases TBK1 and IKKe to inhibit IRF3, while the mechanism of IRF3 
inhibition by MC160 is still unclear. MC160 suppresses IRF7 phosphorylation, which 
was not observed with MC159. Therefore, MC159 and MC160 both inhibit type I IFN 
production, but apparently by different mechanisms (76). The cellular FLIP protein acts 
as a structural homolog to these viral FLIPs, but as you will read in this thesis, it inhibits 
IRF3 and IRF7 by mechanisms distinct from MC159 and MC160. 
There are multitudes of ways viruses evade our immune system. Understanding 
this conflict and elucidating these mechanisms helps us not only further understand the 
signaling pathways involved in type I IFN production, but also provides the basis to 
potentially design therapeutics that exploit these cellular mechanisms for our benefit. 
Clinical implications 
 My interest in type I IFN is inspired by the fact that it is involved in several 
health-related processes including antiviral defense, tumor protection or progression, and 
autoimmunity. The multifunctional roles of type I IFN in human health make it a high 
yield topic of study.  
Early compelling evidence that type I IFN was critical in protecting the host 
against virus infection included experiments performed in IFNAR-/- knock out (KO) 
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mice. In these experiments, viral clearance was greatly decreased when IFNAR -/- mice 
were infected with several different viruses (14; 24). These mice were also more 
susceptible to virus infection than their wild-type counterpart. For example, infection 
with Crimean-Congo hemorrhagic fever virus (CCHFV) and Hazara virus (HAZV) 
resulted in 100% lethality in INFAR -/- mice, supporting the effectiveness of type I IFN 
on limiting viral replication and dissemination (9, 23). Similar phenotypes are observed 
in mice when other critical genes involved in type I IFN signaling (such as STAT1) are 
knocked out (66). Therefore, it was a logical next step that groups began testing 
exogenous IFN for the purpose of treating viral infections. Soon, PEG-ylated IFN 
treatment would become mainstream in patients suffering from infections with hepatitis 
B and C (HBV and HCV) (46), human immunodeficiency virus (HIV) (4) and multiple 
sclerosis (50). Interestingly, research teams are currently investigating the role of 
exogenous type I IFN treatment in the cancer patient. How did we go from viral 
immunity to cancer treatment? The story is one of serendipity.   
The motive to investigate type I IFN in the context of cancer biology began in 
1965 when Gresser et al. tested whether exogenous IFN treatment cured mice of a virus-
induced leukemia. The logic behind these experiments came from the idea that if the 
virus is inducing the leukemia, then simply curing virus infection via IFN treatment 
should therefore cure the cancer. They found that daily injections of concentrated IFN 
preparations increased mouse survival (32). After this success, they tested the efficacy of 
IFN treatment in mice with transplantable tumors. Interestingly, type I IFN limited the 
growth of tumors induced not only by viruses, but also by carcinogens, chemicals, or 
even spontaneous tumors (33). Then, in 2002, Picaud et al. investigated the progression 
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of three different tumor types in either IFNAR-/- mice or mice treated with anti-IFNAR 
antibody. Their work strengthened the work of Gresser et al., because they saw a 
significant increase in growth of tumors when the IFNAR was compromised or knocked 
out (75). These works suggest a strong role for type I IFN in tumor surveillance.  
Finally, there have also been many works investigating the role of type I IFN in 
autoimmune pathologies. As stated earlier in this section, the production of IFN must be 
precisely regulated to maintain beneficial functions such as antiviral defense, tumor 
surveillance and proper immunological responses. When this regulation is disrupted it is 
logical to expect viral dissemination, tumor resistance, and detrimental self-attacking 
immunological complexes (i.e., autoimmunity).  
Without getting too deep into the complexity of linking type I IFN between innate 
and adaptive immunity, IFNs are not only involved the direct attack of viral-infected 
cells, but also involved in priming and preparing cells of the adaptive system to respond 
to viral infection (i.e., DC activation, T helper cell recruitment and activation, and NK 
cell activation) (67). To that end, a surplus of IFN, importantly IFNa, leads to an 
obstruction of the fine-tuned balance of immune health in humans. For example, patients 
with SLE have high levels of IFNa, and concentrations of IFNa correlate to severity of 
disease (how many organs are involved), and dsDNA autoantibody titres (7). Further, 
patients injected with PEG-ylated IFNa for another health condition often produced anti-
nuclear antibodies over the course of treatment (5). Briefly, the pathophysiological 
mechanism behind SLE is initiated by a biological stressor (i.e., UV-induced apoptosis) 
that leads to the release of damaged host DNA and RNA molecules. These PAMPs 
activate pDCs, which are major producers of IFNa. IFNa then engages the JAK/STAT 
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pathway as previously described. In addition to the initiation of ISG production (which 
results in tissue damage), excessive IFNa production also leads to the production of 
autoantibodies produced by B cells (67) (Figure 1.5). This mechanism again highlights 
the critical importance of immunological checks and balances.  
This thesis will continue to return to the theme of balancing type I IFN production 
for the benefit of human health. Utilizing the knowledge of how various pathologies 
arise, along with the discovery of a new and novel regulator of IFN production, (cFLIP), 
I’ve designed experiments with the end goal of 1) identifying the mechanism of how 
cFLIP modulates type I IFN pathways, and 2) exploiting cFLIP for potentially 
therapeutic use.  
 
1.2  FLICE-like Inhibitory Proteins (FLIPs) 
Overview  
FLICE inhibitory proteins (FLIPs) are a family of proteins encoded by both 
viruses (vFLIP; poxviruses, herpesviruses) and cells (cFLIP). FLIPs got their name 
because they each possess tandem death effector domains (DEDs) that were originally 
thought to antagonize cellular apoptotic machinery (such as FLICE, a.k.a caspase-8). 
Interestingly, despite their shared structural homology, FLIPs have demonstrated variable 
roles in modulating different cellular pathways such as apoptosis, NF-kB, and type I IFN 
production. Here, I will discuss the discovery of FLIPs, their structure and how that 





 FLIPs were first discovered because they possess tandem death effector domains 
(DEDs) that are also found in proteins involved in extrinsic apoptosis such as Fas-
associated death domain protein (FADD) and caspase-8. This will be discussed more 
when describing the structure of FLIPs. Interestingly, viral FLIPs were discovered before 
cellular FLIPs when the sequencing of viral genes led to the discovery of regions 
mimicking DEDs found in the previously stated apoptotic proteins (10). Examples of 
FLIPs encoded by viruses include the molluscum contagiosum virus (MCV) proteins 
MC159 and MC160, the Kaposi sarcoma herpes virus (KSHV) protein K13, and the 
herpesvirus type 2 (EHV-2) protein E8. After the discovery of vFLIP genes came the 
discovery of cflar (CASP8 and FADD-like apoptosis regulator), the gene encoding 
multiple splice variants of cellular FLIP (cFLIP) (30). There are multiple splice variants 
of cFLIP, but only three splice variants are detected and therefore thought to be 
successfully translated into protein: the long variant (cFLIPL), and the two short variants, 
cFLIPS and cFLIPR (51). cFLIPL and cFLIPS are the major variants that will be discussed 
in this thesis.  
Structure  
To describe the structure of FLIPs, I find it first important to describe the proteins 
and steps involved in TNF-mediated apoptosis, because FLIPs maintain a structure that is 
critically involved in this pathway. Stimulation of the TNF-receptor 1 (TNFR1) at the cell 
surface by ligands such as tumor necrosis factor (TNF) or TNF-receptor associated ligand 
(TRAIL) leads to recruitment of the TNFR1-associated death domain (TRADD) within 
the cytoplasm. TRADD, containing a death domain (DD), associates with the DD of the 
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Fas-associated death domain (FADD). FADD, also containing a DED, associates with the 
DED of procaspase-8 to initiate its cleavage and activation; this is termed the death 
inducing signaling complex (DISC) (70) (Figure 1.6). FLIPs, containing tandem DEDs, 
can associate with the DED of FADD and/or caspase-8 to modulate apoptotic activity. 
Interestingly, we now know that not all FLIPs modulate apoptosis, an interesting fact 
considering their structure. This will be discussed when describing the different cellular 
pathways that FLIPs modulate. 
FLIPs contain tandem DEDs and a variable C-terminus (Figure 1.7). DEDs 
contain six alpha helices that are involved in protein-protein interactions. Interestingly, 
DEDs have no enzymatic function, and thereby exert their function simply by interacting 
with their targets (90). The sequence similarity of the viral FLIPs MC159 and MC160 
DEDs is ~43% identical while the sequence similarity of the viral and cellular FLIP 
MC159 and cFLIPL is ~ 30% identical, despite all clearly possessing bonafide DEDs 
(12). This in turn makes FLIPs structurally homologous, rather than genetically 
homologous, which may explain why they each have variable functions in the pathways 
that they modulate.  The C-termini of vFLIPs and cFLIPs are highly variable. 
Interestingly, the C-terminus of cFLIPL contains a caspase-like domain (CLD) (Figure 
1.7). To compare, caspase-8 has a caspase domain that is proteolytically cleaved to 
produce an enzymatically active protein. The CLD of cFLIPL is catalytically inactive due 
to several SNPs within the active site, rendering it non-functional (87). You will find in 
Chapter Two of this thesis that the CLD of cFLIPL is the important region involved in 
antagonizing IRF3 activation.  Altogether, the structural hallmark of the FLIP family is 
15	  	  
tandem DEDs, with no two C-termini being alike. With that, they possess various 
functions, which will be covered in the next section.  
Cellular pathways regulated by FLIPs  
My PhD research has been inspired by the multifunctionality of FLIPs as 
modulators of important cellular innate immune responses (IIRs). In this section, I will 
describe three major pathways regulated by viral and cellular FLIPs including apoptosis, 
NF-kB activation, and type I IFN production (via IRF3 and IRF7) (Figure 1.8). Many of 
these mechanisms have been elucidated within the Shisler lab, including my project, 
determining the mechanism by which cFLIP modulates IRF3 and IRF7.  
Apoptosis Earning the name FLICE-like inhibitory protein is an obvious segway 
into the first pathway I will be describing, which is apoptosis, an important pathway 
engaged during viral infection. When viral FLIPs were discovered to contain tandem 
DEDs, I imagine the rational experimental question became “do these proteins antagonize 
apoptotic machinery that possesses similar structural domains?”  Indeed, Bertin et al. and 
Thome et al. found that herpesvirus type 2 FLIP E8 and MCV’s MC159 antagonize 
Fas/TNFR1-induced apoptosis specifically mediated by interactions between their DEDs 
and FADD (10, 95). Hu et al. also investigated vFLIPs MC159, MC160 and E8, 
confirming MC159 and E8 are inhibitors of TNFR1-induced apoptosis, as well as MC160 
(39). In contrast, Shisler and Moss found that co-transfection of cells with plasmids 
encoding MC159 and MC160 demonstrated no amplified inhibition of apoptosis 
compared with cells only MC159, suggesting MC160 isn’t actually an inhibitor of 
apoptosis (Figure 1.8). They also found that while MC159 immunopreciptates with Fas, 
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while MC160 does not (91). These findings suggest that MC160, despite containing 
tandem DEDs, does not inhibit TNFR1-induced apoptosis.  
cFLIP regulation of apoptosis is messy because there are several contradicting 
reports on the function and mechanism of cFLIP in apoptosis. Scaffidi et al., determined 
to hash out the role of cFLIP in apoptosis, found that its function was dependent on its 
expression levels. At high levels, cFLIP completely blocks TNFR1-mediated apoptosis 
(Figure 1.8). Controversially, immunoprecipitations in this study revealed that both 
isoforms, cFLIPL and cFLIPS were recruited to the DISC, but interestingly did not 
immunoprecipitate with FADD or caspase-8, despite inhibiting caspase-8 processing 
(87). It is now widely accepted that cFLIPL and cFLIPS do in fact bind to procaspase-8 at 
the DISC and the composition of the heterodimer determines procaspase-8 activation or 
inhibition (40). Again, despite their structural similarities, FLIPs demonstrate variable 
roles in modulating apoptosis. Further, expression levels of FLIPs add to the complexity 
of their function. 
NF-kB pathway As the field investigating FLIPs in innate immune responses 
(IIRs) kept growing, NF-kB became a target of interest likely because TNFR1 
engagement, like in apoptosis, leads to NF-kB activation via TRADD. A complex 
including TRADD, TNF-associated receptor 2 (TRAF2) and receptor interacting protein 
(RIP) leads to I kappa B kinase complex (IKK) activation. IKK phosphorylates IkBa, the 
inhibitor of NF-kB within the cytoplasm. IkBa phosphorylation leads to its 
ubiquitination and degradation, freeing NF-kB, whereby NF-kB translocates to the 
nucleus to drive transcription of pro-inflammatory genes (Figure 1.6) (13). The Shisler 
group characterized MC159 and MC160 as inhibitors of NF-kB (Figure 1.8). Biswas and 
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Shisler published that MC159 prevents IKKg ubiquitination, while Nichols and Shisler 
published that MC160 promotes IKKa degradation (11, 71). K13 interestingly activates 
the NF-kB pathway by interacting with IKKg, independent of factors involved in 
downstream NF-kB activation, TNF-receptor associated receptor 6 (TRAF6) and TGFb 
activated kinase 1 (TAK1) (Figure 1.8) (65). cFLIP, specifically its N-terminal cleavage 
product of 22 kDa, activates NF-kB by interacting with IKKg (Figure 1.8) (29). In section 
1.3 I will go into more detail about how cFLIP promotion of NF-kB activation and 
inhibition of apoptosis has major clinical implication in tumor biology.  
IRF3 pathway The IRF3 pathway of activation was previously described in 
section 1.1 (Figure 1.1). IRF3 activity is critical during viral infection to induce 
protective ISGs that limit viral dissemination. Naturally, viruses have evolved to 
antagonize IIRs by encoding immunomodulatory proteins. FLIPs are one such family of 
proteins. It was first appreciated that vFLIPs possess an IRF3 inhibitory function when 
Randall et al. overexpressed vFLIPs (MC159, MC160, and K13) and showed MC159 and 
MC160 could inhibit IRF3-driven IFNb transcription while K13 had little to no effect 
(76). They also tested cFLIPL after the first indication that cFLIP could inhibit IRF3 was 
published by Handa et al. in 2011. Both groups were in agreement that cFLIPL inhibits 
IFNb production, but Randall and Shisler showed that FLIPs inhibiting IFNb 
transcription was due to inhibition of IRF3 activation because they performed 
experiments in cells lacking NF-kB, a transcription factor included in the IFNb promoter 
(Figure 1.8). MC159 inhibits IRF3 likely via interactions with the kinase complex TBK1-
IKKe, preventing TBK1 phosphorylation and downstream signaling. MC160 also inhibits 
TBK1 phosphorylation, but does not co-IP with TBK1-IKKe. How MC160 inhibits IRF3 
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is still somewhat of a mystery, but after TBK1 stimulation, MC160 is able to inhibit IRF7 
phosphorylation, suggesting it possesses more than one mechanism to oppose type I IFN 
production (76).  
Finally, one of the major projects that this thesis focuses on is the mechanism by 
which cFLIPL inhibits IRF3 activity. This will be largely covered in Chapter Two. 
Briefly, the CLD of cFLIPL interacts with IRF3 and prevents IRF3-IFNb promoter 
binding within the nucleus (26). This is the first FLIP and one of the few regulatory 
proteins to exert its function within the nucleus, making it a novel inhibitory molecule. 
This mechanism contradicts the popular hypothesis that cFLIPL indirectly inhibits IRF3 
because it inhibits caspase-8. Caspase-8 mediates the cleavage of IRF3, which leads to 
IRF3 ubiquitination and degradation (88). Further support that cFLIPL does not inhibit 
IRF3 by this mechanism is that in cells overexpressing cFLIPL, IRF3 levels are not 
changed, as would be expected if caspase-8 were mediating IRF3 degradation (26).  
To end, it should be appreciated by now that despite the structural homology of 
the FLIP family, slight amino acid differences in these proteins result in altogether 
different functions on the IIRs discussed. Therefore, these proteins are not redundant, 
rather playing a specific role in either antagonizing host IIRs (vFLIPs) or regulating host 
IIRs (cFLIP).  
 
1.3  Cellular FLICE-like Inhibitory Protein (cFLIP) 
Overview  
Regulation of various innate immune responses and cellular maintenance 
pathways within the host is critical for avoiding pathological outcomes such as 
19	  	  
autoimmunity, cancer, and immunodeficiency. Cellular FLICE-like inhibitory proteins 
(cFLIPs) have proven to be quite multifunctional in respect to regulating pathways that 
are involved in these diseases (110). One such pathway includes apoptosis, which is a 
highly regulated process important for removal of exhausted cells, the maturation of 
immune cells (importantly T cells) and limiting infections (72). When cFLIP expression 
levels are too high, uncontrolled proliferation can result in cancer. When levels are too 
low, aberrant cell death can result in cellular atrophy and immunodeficiency (72, 110). In 
addition, cFLIP is an activator of the NF-kB pathway, which contributes majorly to 
inflammation. It’s constitutive regulation, which can result from cFLIP overexpression, is 
seen in many different types of human cancers because it controls genes involved in 
cellular proliferation and protection against stimuli that would otherwise engage cell 
death (100). Therefore, misregulation of cFLIP therefore has detrimental effects, for 
example, Yeh et al., discovered that cFLIP-/- mice are embryonically lethal due to heart 
failure. This was one of the first indications that cFLIP is critical for normal host 
functioning (104). 
Here, I plan to give a detailed background on cFLIPs as well as describe the 
importance of balancing cFLIP levels within the host to maintain proper cellular 
functions. In respect to type I IFN regulation by cFLIP, a more recently explored field, I 
plan to describe how this function may also contribute greatly to pathologies I have 
already mentioned above, which after all is the inspiration and importance of my work.  
Transcription and translation  
The clfar gene encoding cFLIP is located on chromosome 2. Again, CFLAR 
encodes multiple splice variants of cFLIP, but only cFLIPL (55 kDa), cFLIPS (25 kDa), 
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and cFLIPR (24 kDa) are translated into functional proteins (Figure 1.8) (42).  cFLIPL and 
cFLIPS are the two major isoforms expressed in humans. The N-terminus of cFLIP is 
structurally similar to procaspase-8 because they each variant contains tandem DEDs. 
The CLD of cFLIPL is functionally inactive due to several amino acid substitutions within 
motifs involved in caspase processing. Therefore, cFLIPL may itself be cleaved by other 
caspases, but no longer possess its own catalytic activity (42). Post-translational cleavage 
of cFLIPL has been demonstrated at site D376 resulting in p43-FLIP while cleavage of 
cFLIPL and cFLIPS at D196 generates p22-FLIP. These cleavage products serve 
biological purposes that will be described in subsections below (Figure 1.9) (110).  
The role of cFLIP in tumor biology  
In section 1.2, I discussed the various pathways controlled by FLIPs (Figure 1.8). 
cFLIP in particular inhibits apoptosis and activates the NF-kB pathway, making it a 
prime contributor to the tumor microenvironment.  
Proper induction of apoptosis in cells that have seen their last days is critical for 
preventing tumor development. At high concentrations, cFLIPL recruitment to the DISC 
will inhibit procaspase-8 processing resulting in a halt of apoptosis. A similar mechanism 
is seen with cFLIPS at lower expression levels (110). Further, NF-kB activation is 
cytoprotective because it leads to the induction of genes involved in antagonizing 
apoptosis for cell survival, thereby making a key player in respect to tumor resistance 
(28). Through cFLIP-IKK complex interactions, cFLIPL or cFLIPS activate NF-kB (6). 
Many cancers over-express cFLIP and therefore, the combination of opposing apoptosis 
and activating NF-kB have made cFLIP a major target for cancer therapy (85).  
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Defects in apoptosis are commonly observed in cancers that do not respond to 
drug therapies. There have been many investigations to identify what causes cancer cells 
to be resistant to inducing apoptosis. Higher expression of inhibitors of apoptosis such as 
cFLIP no doubt plays a role in tumor persistence. This was demonstrated when human 
leukemia cells began responding to taxol treatment; cFLIP was downregulated and 
caspase activation was initiated (22). This led to targeting cFLIP directly and studying the 
tumor apoptotic response. Groups began developing siRNAs to target cflar, and found 
that by decreasing cFLIP expression, non-small cell lung cancer (NSCLC), colorectal 
cancer, and prostate cancer cells were sensitized to TRAIL-induced apoptosis in vitro 
(62). Safa et al. also developed lipocomplexes of cFLIP siRNA for in vivo delivery, 
successfully knocking down cflar in MCF-7 breast cancer xenografts in mice, leading to 
induction of apoptosis. While initiation of apoptosis is a very important process in 
preventing tumor progression or even shrinking tumors, the NF-kB pathway is also 
involved in promoting tumor persistence.  
NF-kB promotes tumorigenesis by (i) encoding anti-apoptotic genes, (ii) 
promoting cell survival, and (iii) increasing tumorigenic angiogenesis (48). There are 
many cancers that demonstrate constitutive activation of NF-kB and drugs that inhibit 
NF-kB activation have proven success in cancers such as multiple myeloma (MM) (35). 
Ideas of knocking down cFLIP to decrease NF-kB activation have not been explicitly 
studied, but it widely accepted that this might also contribute to tumor protection (85).  
In summary, the tumor microenvironment is a very complex system, exploiting 
host pathways like apoptosis and NF-kB activation for tumor growth and development. 
These pathways need to be targeted for successful therapy response. The next section will 
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discuss another pathway, that of type I IFN production, which has also been debated for 
its role in tumor protection. As an inhibitor of type I IFN, targeting cFLIP may provide 
additional therapeutic advantage.  
 
1.4  cFLIP Regulation of Type I IFN 
Overview  
Regulation of type I IFN is one of the most recent cFLIP functions identified. Due 
to the structural similarity of cFLIP and vFLIPs (which are well known IFN antagonists), 
it was inevitable that scientists would test this function for cFLIP. In addition, with the 
knowledge that caspase-8 activation can lead to IRF3 cleavage (88), groups hypothesized 
that regulation of caspase-8 by cFLIP would indirectly have an effect on IRF3 activity. 
Before my work, there were only a few reports describing cFLIPL and cFLIPS with 
respect to type I IFN regulation and, as science goes, the publication contradicted each 
other as discussed below. In this section, I will be discussing the results from previous 
investigations of cFLIP and type I IFN regulation, as well as briefly describe the 
mechanisms of cFLIP-mediated inhibition of IRF3 and IRF7 activity that I have 
uncovered during my PhD research. Finally, I will describe why studying these 
mechanisms are clinically important, hopefully aiding in the future development of 
therapies for IFNmediated pathologies like autoimmunity or tumorigenesis. 
Previous investigations of cFLIP control of type I IFN regulation  
Sears et al. published a 2011 study showing that caspase-8 activation leads to 
IRF3 ubiquitination and proteasome-mediated degradation. When they mutated the 
critical cleavage site within IRF3, caspase-8 could no longer cleave IRF3 resulting in 
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IRF3’s protection from degradation. This study suggested that caspase-8 plays a role in 
regulating dsRNA-dependent gene induction by regulating IRF3 (88).  That same year, 
Handa et al. investigated cFLIP as a suppressor of IRF3-mediated signaling. The 
rationale was that, since cFLIP is an inhibitor of caspase-8, perhaps cFLIP also inhibits 
IRF3 activation (34). In support of this hypothesis, they found that in cFLIP-/- MEFs, 
poly (I:C)-induced IFNb mRNA expression was greatly increased compared to WT cells, 
suggesting cFLIP inhibits IFNb expression in response to dsRNA. Further, when they 
incubated cFLIP -/- cells with the caspase-8 inhibitor, z-vad-fmk, IFNb levels did not 
change, suggesting that inhibiting caspase-8 does not have a major effect on controlling 
IFNb levels (34).  
While IFNb production is greatly regulated by IRF3, Handa et al. did not 
explicitly show that cFLIP inhibits IFNb production via IRF3. Recall that the IFNb 
enhancesome contains binding domains for multiple transcription factors, including NF-
kB and IRF3. Randall et al. showed that cFLIPL indeed inhibits IFNb-luc activity 
independent of NF-kB when she performed luciferase assays in MEFs devoid of the NF-
kB (76). These data provided stronger evidence that cFLIPL inhibition of IFNb 
production is by modulating IRF3 activity. 
Contradictory to the reports above, Buskiewicz et al. published that cFLIPL-
expressing MEFs infected with Coxsackievirus B3 (CVB3) demonstrated elevated levels 
of IFNb secretion and enhanced caspase-8 activity while cFLIPS reduces type I IFN and 
caspase-8 activity in cFLIPS-expressing cells infected with CVB3. They further showed 
that MAVS-caspase-8 interactions are enhanced in the presence of cFLIPL and reduced in 
the presence of cFLIPS, suggesting MAVS-caspase-8 complex activity leads to increased 
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type I IFN production (15). Therefore, these data would suggest that cFLIPL can activate 
IRF3 activity, while cFLIPS does not.  
The above opposing results for cFLIP modulating type I IFN production may be 
due to the different cell types used in each study (MEFs, 293Ts, etc.), cFLIP protein 
expression levels, and reagents used to stimulate IRF3 activation (poly I:C, expression 
plasmids, virus infection, etc.).  For my research studies, I aimed to elucidate biochemical 
mechanisms by first utilizing cell lines that are easy to work with and then confirming the 
mechanism in physiologically relevant cell lines. In the next subsections, I will describe 
how I elucidated the mechanism of IRF3 and IRF7 inhibition by cFLIP, the most in-depth 
study of cFLIP’s role in type type I IFN modulation to date. 
cFLIP and IRF3  
Randall et al. investigated the role of FLIP’s in modulating type I IFN production. 
They discovered that MC159, MC160 and cFLIPL inhibit IFNb-luc activity in cells 
lacking NF-kB. They further published that MC159 and MC160 significantly inhibit 
TBK1- and IKKe-induced activation of the PRDIII-promoter (IRF3 specific), and went 
on to describe those mechanisms (76). I became interested in the cellular structural 
homolog of vFLIPs, cellular FLIP (cFLIP) due to its multifunctional roles in various 
pathological diseases. I picked up the project of elucidating the mechanism by which 
cFLIPL antagonizes IFNb-driven transcription. I first wanted to test if cFLIPL also 
inhibited the IRF3-specific PRDIII-luc promoter, like MC159 and MC160. Indeed, 
during MVA infection, poly I:C stimulation, or overexpression of TBK1, cFLIPL 
significantly inhibits PRDIII-luc activity. To further support cFLIPL acts on IRF3, 
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decreased expression of ISGs under the control of IRF3, isg15 and isg54, were observed 
in the presence of cFLIPL.  
Since cFLIPL inhibited TBK1 and IKKe-induced PRDIII-luc activity, this 
suggested it works at the level of the TBK1-IKKe complex or downstream (i.e. IRF3 
phosphorylation, nuclear translocation, etc.). A convenient way to test if a regulator acts 
directly on IRF3 activation itself is to utilize a phosphomimetic mutant of IRF3. When 
overexpressed, PRDIII-luc activity is induced, and only if the regulator acts after IRF3 
phosphorylation would you see inhibition of PRDIII-luc activity. Indeed, cFLIPL inhibits 
this constitutively active IRF3 mutant. Further, cFLIPL does not effect IRF3 
phosphorylation stimulated by overexpression of TBK1. These data suggest cFLIPL acts 
on event in the IRF3 signaling pathway downstream of IRF3 phosphorylation. After IRF3 
is phosphorylated, it dimerizes and translocates into the nucleus (45).  
I tested IRF3 nuclear translocation in the presence and absence of cFLIPL. IRF3, 
upon TBK1 over-expression, translocated into the nucleus, even in cFLIPL-expressing 
cells, suggesting cFLIPL inhibits IRF3 within the nucleus. To test if nuclear IRF3 could 
successfully bind to its promoter site, I utilized a chromatin immunoprecipitaion (chIP) 
assay. In this assay, I fixed cells such that transcription factors would be cross-linked to 
their respective DNA binding sites. I IP’ed IRF3 in stimulated or unstimulated cells 
expressing either empty vector or pcFLIPL and asked if I could PCR amplify the ifnb1 
promoter.  Interestingly, levels of ifnb1 DNA were significantly decreased in stimulated 
cells expressing cFLIPL compared to empty vector suggesting that cFLIPL inhibits IRF3 
recruitment to the IFNb promoter.  
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I wanted to investigate how cFLIPL prevented IRF3-DNA binding. The IRF3 co-
factor, CREB-binding protein (CBP), is a histone acetyltransferase that is critical for co-
activation of the IFNb promoter (68). I performed a co-IP to test IRF3-CBP interactions 
in the presence of cFLIPL and found that cFLIPL prevented IRF3-CBP interactions. 
Likewise, cFLIPL co-IPed with IRF3. These data suggested a mechanism where via 
IRF3-cFLIPL interactions, IRF3-CBP interactions are disrupted resulting in loss of IRF3 
recruitment to the IFNb promoter.  
I wanted to test this mechanism in a physiologically relevant system. cFLIP is 
overexpressed in many cancers including NSCLC, colon cancer, and pancreatic cancer 
(85). I preformed an in silico analysis that revealed in these cancers, ISG’s controlled by 
IRF3 are also down-regulated (81). I utilized cell lines derived from patients with these 
respective cancers (A549, NSCLC; HCT116, colorectal carcinoma; AsPC-1, pancreatic 
adenocarcinoma).  In each cell line, I treated cells with or without poly I:C, a TLR3 
agonist, and IPed cFLIP. cFLIPL-IRF3 interactions were observed during stimulation, 
confirming these interactions are physiologically relevant. In addition, I silenced cFLIP 
in the A549 cell line to test ISG expression during TLR3 stimulation. isg15 and isg54 
mRNA levels were significantly increased in stimulated cells when cFLIPL was silenced, 
suggesting cFLIPL over-expression in A549 cells suppresses IRF3-driven transcription.  
All together, these data suggest that cFLIPL regulates IRF3-driven transcription in 
cancer cells by preventing IRF3-DNA interactions. This may provide yet another 




cFLIP and IRF7  
IRF3, IRF5, and IRF7 are structurally similar transcription factors in that they 
each contain an N-terminal DNA-binding domain (DBD), centrally located IFN 
association domains (IAD) and C-terminal signal response domains (SRDs) (58, 86, 109) 
(Figure 1.10). Due to these structural similarities, I hypothesized that cFLIPL may also 
modulate IRF5 or IRF7. While IRF3 and IRF7 are the main drivers for type I IFN 
expression (IFNb and IFNa), IRF5 is involved in driving transcription of genes also 
under the control of NF-kB (i.e. il12p40, il6, tnfa) (78). IRF5 and IRF7 can be activated 
via TLR7/8/9 ligation (37), while IRF3 and IRF7 can be activated via RIG-I or TLR3 
activation (described in section 1.1). Due to the cross talk of pathways that can activate 
both IRF3 and IRF7 (i.e. RIG-I) or activate both IRF5 and IRF7 (i.e. TRL7/8 and TLR9), 
I wanted to develop a system to study IRF5 and IRF7 in isolation.  
We previously published that the IRF3CA mutant activates the PRDIII-luc 
reporter, and this activity is inhibited by cFLIPL (26). Other groups have shown that co-
over-expressing IRF5 and TRAF6 in 293T cells leads to il12p40-luc activity (78), while 
over-expressing IRF7 in 293T cells leads to ifna-luc activity (59). I decided to over-
express IRF3CA, IRF5 and TRAF6, or IRF7 in 293T cells transfected with either the 
il12p40-luc reporter or the ifna6-luc reporter to IRF5 or IRF7 in isolation. IRF3CA did 
not activate the il12p40- or ifna6-luc reporters. IRF5 and TRAF6 overexpression only 
induced il12p40-luc activity, but not ifna6-luc activity in my hands (previous reports 
have shown that IRF5, TRAF6, MyD88, and ubiquitin over-expression minimally 
activates the ifna4-luc reporter (103). IRF7 over-expression did not activate the il12p40-
luc reporter; it only activated the ifna6-luc reporter. cFLIPL over-expression in these 
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systems demonstrated inhibition of IRF7-induced ifna6-luc activity, but not IRF5-
induced il12p40-luc activity suggesting it acts on IRF7, but not IRF5.  
IRF5 and IRF7 activity varies in response to different classes of CpG ODN 
stimulation. IRF5 induces il12p40, il6, and tnfa in response to class B CpG, while IRF7 
induces ifna in response to class A CpG ODN (Razaei, 2016; 20). To further confirm 
IRF7 but not IRF5 are inhibited by cFLIPL, I stimulated HeLa cells with CpG-A to 
induce ifna6-luc activity. In the presence of cFLIPL, CpG-A-induced infa6-luc activity 
was significantly decreased, suggesting cFLIPL inhibits IRF7 activation.  
With these important controls out of the way, I began to elucidate the mechanism 
by which cFLIPL inhibits IRF7. The first logical question was whether or not cFLIPL co-
IPs with IRF7, since cFLIPL acts on IRF3 via protein-protein interactions. I performed a 
co-IP experiment with cFLIPL and IRF7 in 293T cells over-expressing IRF7 and cFLIPL 
as well as a co-IP experiment with HeLa cells over-expressing cFLIPL and expressing 
endogenous IRF7 protein. Interestingly, cFLIPL did not co-IP with IRF7 in either cell 
line, while under the same conditions, cFLIPL co-IPed with IRF3 (as previously seen). 
These results suggested to me that cFLIPL acts on IRF7 by a different mechanism than 
IRF3.  
Like IRF3, IRF7 phosphorylation is critical for expression of IFNa. I tested the 
status of IRF7 phosphorylation in CpG-A-stimulated HeLa cells over-expressing cFLIPL. 
Level of phosphorylated IRF7 were significantly decreased in cFLIPL-expressing cells, 
suggesting cFLIPL acts by inhibiting an even upstream of IRF7 phosphorylation.  
Two major signaling proteins essential in prepping IRF7 for activation include 
TRAF6 and IKKa (section 1.1). TRAF6 ubiquitination of IRF7 leads to recruitment of 
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IKKa, and IKKa ultimately phosphorylates IRF7 (49, 38). To begin to pin down the 
portion of the IRF7 signal transduction pathway that cFLIPL targets, I tested whether 
IRF7-TRAF6 or IRF7-IKKa interactions were disrupted by cFLIPL. Interestingly, 
TRAF6 and IRF7 co-immunoprecipitated in cells lacking or expressing cFLIPL, 
suggesting these interactions were not abrogated. On the other hand, IRF7-IKKa 
interactions were disrupted in the presence of cFLIPL, suggesting cFLIPL may inhibit 
IRF7 phosphorylation by blocking IRF7 from interacting with the kinase , IKKa,  critical 
for IRF7 phosphorylation. Finally, I have data that suggests that IRF7-IKKa interactions 
are disrupted because cFLIPL co-IPs with IKKa.  
Importantly, I tested IRF7 inhibition in a physiologically relevant system. The 
THP-1 human monocyctic cell line, differentiated into macrophage-like cells with PMA, 
responds to CpG-A stimulation (94). In addition, pDCs are the major producers of IFNa 
and constitutively express IRF7 (52). I utilized the CAL-1 pDC cell line established from 
a patient with lymphoma as surrogate for studying primary pDCs (64). I transduced these 
cell lines with a lentivirus to yield cell lines over-expressing cFLIPL. When these cFLIPL-
over-expressing cells are stimulated with CpG-A, there is significantly less ifna4 and 
infa6 mRNA expression than cells transduced with a control lentivirus, suggesting 
cFLIPL inhibition of infa is physiologically relevant. Immunoprecipitation experiments 
testing IRF7-IKKa interactions were confirmed in CAL-1 cells when IKKa was 
immunoprecipitated in cFLIPL-expressing cells and IRF7 interactions were not detected, 
but cFLIPL interactions were apparent.  
All together, these data suggest that cFLIPL modulates type I IFN production by 
two distinct mechanisms.  Importantly, pDC production of IFNa has been implicated in 
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autoimmunity. By elucidating this new mechanism, it may provide useful to exploit 
cFLIPL for its IRF7 inhibitory function, since overexpressing cFLIPL in CAL-1 cells 
demonstrated a decrease in ifna mRNA expression. 
 
1.5 Thesis Outline 
cFLIP is a potent inhibitor of Type I IFN 
  The goal of my thesis project was to characterize the molecular mechanisms of 
cFLIP-mediated inhibition of type I IFN production. Based on previous studies in our lab, 
we hypothesized that cFLIPL but not cFLIPS, inhibited IFNb expression by inhibiting the 
transcription factor IRF3, a mechanism shared by other FLICE-like inhibitory proteins 
(FLIPs), like MC159 and MC160. My data suggest that cFLIPL inhibits IFNb production 
by interacting with IRF3 and preventing IRF3-CBP-DNA interactions. In addition, my 
data suggest that both cFLIPL and cFLIPS antagonize IRF7 to prevent IFNa production. 
Results suggest that cFLIP inhibits IRF7 phosphorylation, likely via cFLIP-IKKa 
interactions. cFLIP co-IPs with IKKa and correlates to a loss of IKKa-IRF7 interactions, 
which are critical for IFNa production.  Altogether, cFLIP utilizes multiple mechanisms 
to shut down type I IFN expression.  
Characterization of cFLIPL in the IRF3 pathway (Chapter 2) 
   Here I will thoroughly describe the characterization of cFLIPL as a potent 
inhibitor of IRF3-driven IFNb expression. Here I show that cFLIPL, specifically the CLD 
of cFLIPL, antagonizes IRF3 activity by binding to IRF3, preventing IRF3-CBP 
interactions, and further, recruitment to the IFNb promoter.  
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Characterization of cFLIPL in the MyD88-dependent IRF7 pathway (Chapter 3) 
 Here I will thoroughly describe the characterization of cFLIPL and cFLIPS as 
inhibitors of IRF7 phosphorylation and downstream inhibition of IFNa expression. I 
demonstrate that cFLIPL and cFLIPS prevent IRF7 phosphorylation during CpG-A 
stimulation. cFLIPL disrupts IRF7-IKKa interactions, which are critical for IRF7 
phosphorylation and downstream signaling events. I hypothesize that this is because 
cFLIPL co-IPs with IKKa to prevent further signaling.  
Cytokine expression in a cerulein-induced model of acute pancreatitis (Chapter 4) 
  In Chapter 4 I will discuss measuring il6 and cinc1 cytokine mRNA expression in 
rats injected with cerulein. Cerulein induces acute pancreatitis in various animal models, 
and il6 and cinc1 are important biomarkers for acute pancreatitis. We wanted to test the 
expression of these cytokines at early and late time points (ranging from 0 h to 60 h).  
Summary of thesis and future directions (Chapter 5)  
Here I will summarize the thesis and describe future directions for IRF7-induced 
IFNa project. This will include an experimental design that I had hoped to investigate. 
Briefly, I hoped to transduce normal PBMCs and PBMCs from an SLE patient with a 
lentivirus overexpressing cFLIP. I hoped to see ifna expression was decreased in cFLIP-
expressing diseased PBMCs. This would have indicated to me that cFLIPL could be a 








Figure 1.1 Pathway for expression of IFNb, IFNa, and Interferon Stimulated Genes 
(ISGs). Left panel: Viral replication byproducts like dsRNA are recognized by 
endosomal TLR3 or cytoplasmic sensors like MDA-5 and RIG-I. The adapter protein, 
MAVS, recruits kinases TBK1 and IKKe, which form a complex and phosphorylate IRF3 
and IRF7. IRF3 dimerizes, translocates to the nucleus, and drives expression of IFNb and 
ISGs. Right panel: Viral replication byproducts like ssRNA or PAMPs like unmethylated 
CpG DNA activate endosomal TLR7/8 and TLR9 respectively. MyD88 is recruited to the 
cytoplasmic portion of TLRs followed by IRAK1, IRAK4 and TRAF6. IRAK4 
autophosphorylates IRAK1. IRAK1 kinase activity is important for IRF7 activation. 
TRAF6 ubiquitinates IRF7, followed by phosphorylation by IKKa. IRF7 dimerizes, 
translocates to the nucleus, and drives expression of IFNa and ISGs. Production of IFNa 
and IFNb also activates IFNAR on the cell surface leading to ISGF3 complex formation, 
nuclear translocation, and production of ISGs.  
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Figure 1.2 Type I IFNmediated JAK/STAT signaling pathway. Type I IFNs (IFNa, 
IFNb) bind to the IFNAR at the cell surface. JAK1 and Tyk2 kinases are recruited to the 
cytoplasmic portion of the IFNAR. JAK1/Tyk2 phosphorylate STAT1 and STAT2, 
which form a complex with IRF9, termed ISGF3. This complex translocates to the 






Figure 1.3 Cellular regulation of Type I IFN expression. Left panel: FoxO1 and 
RAUL promote IRF3 degradation within the cytoplasm. The PP2A-RACK1 complex 
dephosphorylates IRF3 in the cytoplasm. TRIM26 promotes IRF3 degradation within the 
nucleus. Right panel: RAUL promotes IRF7 degradation within the cytoplasm. The 
PP2A-RACK1 complex dephosphorylates IRF7 in the cytoplasm. TRIM26 promotes 









Figure 1.4 Viral inhibition of Type I IFN expression. Left panel: IAV protein, NS1, 
inhibits RIG-I sensing of dsRNA. MCV protein, MC159, inhibits TBK1 phosphorylation. 
MCV protein, MC160, inhibits TBK1-induced IRF7 phosphorylation. KSHV protein, 
RTA, recruits cellular RAUL to promote IRF3 degradation. Rotavirus protein, NS1, also 
promotes IRF3 degradation. Right panel: RTA recruites RAUL to promote IRF7 










Figure 1.5 Pathological mechanism for autoimmunity as a result of excessive IFN 
production. The pathophysiological mechanism behind system lupus erythematosus is 
initiated by a biological stressor (i.e., UV-induced apoptosis) that leads to the release of 
damaged host DNA and RNA molecules. These PAMPs activate cells which produce 
IFNs that stimulate B cells. B cells produce autoantibodies against host DNA. These 
immune complexes activate pDCs, which are major producers of IFNa. Large amounts 














Figure 1.6 TNFR1-mediated apoptosis and NF-kB activation. Apoptosis: stimulants 
like TNF or TRAIL bind to the TNFR1 lead to the recruitment of TRADD, FADD, and 
procaspase-8 forming the death induced signaling complex (DISC). Procaspase-8 is 
cleaved and activated to caspase-8. Caspase-8 activates downstream caspases to initiate 
apoptosis. NF-kB: Engagement of the TNFR1 leads to a complex containing TRADD, 
TRAF2, and RIP. Subsequent activation of the IKK complex leads to the 
phosphorylation, ubiquitination, and degradation of the inhibitor of NF-kB, IkBa. Free 









Figure 1.7 Schematic reorientation of viral and cellular FLIPs. FLIPs contain tandem 
death effector domains (DEDs), which are important for protein-protein interactions. 

















Figure 1.8 Summary of FLIP modulations of various cellular pathways. cFLIPL can 
activate apoptosis at low concentrations, and inhibit apoptosis at high concentrations. 
cFLIPS and MC159, and K13 inhibit apoptosis, while MC160 has no effect. cFLIPL, 
cFLIPS, and K13 activate NF-kB while MC159 and MC160 inhibit NF-kB activation. 
cFLIPL, MC159 and MC160 inhibit IRF3 activity, while cFLIPS and K13 have no effect 
on IRF3 activity. Currently, cFLIPL and cFLIPS are the only known FLIPs that modulate 













Figure 1.9 Alternative splice variants and cleavage products of cFLIP. cFLIPL 
contains a C-terminal caspase-like domain (CLD). cFLIPS and cFLIPR are expressed as 
shorter splice forms, lacking a CLD. cFLIPR is a result of an early stop codon in the cflar 
gene and yields a protein 6 aa shorter than cFLIPS. cFLIPL can be cleaved by caspase-8 at 
D376 to yield p43-FLIP. cFLIPL and cFLIPS can be cleaved by caspase-8 at D196 to 















Figure 1.10 Schematic representation of IRF3, IRF5, and IRF7 proteins. IRF3, IRF5, 
and IRF7 contain N-terminal DNA binding domains (DBD), central interferon 
association domains (IAD), and C-terminal signal recognition domains (SRD). IRF7 has 
in inhibitory domain that keeps IRF7 in a monomer form until it is phosphorylated. 
Phosphorylation sites are found within the SRD of each IRF. IRF3 is phosphorylated at 
various Ser and Thr residues by TBK1 and IKKe. IRF5 is phosphorylated at sites within 
the SRD that have yet to be identified. The kinase important for IRF5 phosphorylation 
has yet to be identified. IRF7 is phosphorylated at various Ser residues within the SRD. 
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Chapter 2: cFLIPL interrupts IRF3-CBP-DNA interactions to inhibit IRF3-driven 
transcription  
Originally published in The Journal of Immunology. Lauren Gates-Tanzer and Joanna L. 
Shisler. 2016. cFLIPL interrupts IRF3-CBP-DNA interactions to inhibit IRF3-driven 
transcription. J. Immunol.197:923-933. Copyright © [2016] The American Association 




Type I IFNs (IFNa, IFNb) are very important cytokines for human health. They 
are produced in response to virus infection (14). The administration of type I IFN inhibits 
tumor growth in experimental animals and in some human tumors (45). However, this 
same immune response must be carefully controlled.  For example, increased type I IFN 
levels cause disease symptoms associated with autoimmunity (36). Thus, there is a 
cellular regulatory network that precisely modulates type I IFN production to avoid 
deleterious imbalances in the immune response.  
The cellular proteins that control type I IFN production are well-known (14, 21, 
16). This includes apical cellular molecules (e.g., MAVS, TLR3) that recognize microbial 
PAMPs or cancer DNA, and intermediate signaling molecules (e.g. TBK1, IKKe) that 
directly stimulate IRF3 via phosphorylation. IRF3 then dimerizes, and translocates to the 
nucleus. IRF3 forms an enhanceosome (28, 51, 55), where IRF3 binds to specific 
recognition sequences in promoters for genes encoding IFNb and interferon-stimulated 
genes (ISGs) (23, 39, 51, 55). Importantly, cofactors like CREB-binding protein (CBP) 
must also be recruited to IRF3 for effective IRF3-controlled transcription (55).  
Healthy cells must down-regulate or prevent type I IFN production. Several 
cellular proteins are known to inhibit IRF3 to this end. These include TRIM26 (49), 
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PPA2 (25), RACK1 (25), FoxO1 (22) and RAUL (57).  Most of these proteins bind to 
and modify the transcriptionally active IRF3 to ultimately induce IRF3 proteosomal 
degradation. In contrast, PPA2 binds to and dephosphorylates transcriptionally active 
IRF3 to halt IRF3-driven transcription (25). Regardless, the study of cellular inhibitory 
mechanisms is critical to rationally control type I IFN to avoid deleterious imbalances in 
the immune response.   
cFLIPL was originally characterized as an anti-apoptosis protein, which has made 
it an attractive target for cancer therapies (41).  cFLIPL also is critical for the 
development of embryos (54), macrophages (15) and T cells (8), and for lymphocyte 
proliferation (5, 8). Several publications show that cFLIPL regulates type I IFN 
production (6, 13, 33), which would impact the current thinking about how cFLIPL 
performs its known functions. However, these reports show opposing effects of cFLIPL, 
in which cFLIPL induces or inhibit type I IFN production (6, 13, 33). Regardless, the 
molecular mechanism for this cFLIPL function remains unknown. This is an important 
gap in knowledge if the scientific community expects to understand how to regulate 
cFLIPL and IRF3 activation to achieve proper immune responses and immune system 
homeostasis (36, 37).  
Type I IFN production is controlled by several transcription factors, including 
NF-kB, IRF3 and IRF7 and AP1 (16). To ask how cFLIPL inhibits type I IFN production, 
we used several approaches to stimulate and detect IRF3 activation independent of these 
other transcription factors. We found that cFLIPL inhibited IRF3-induced gene 
transcription triggered by virus infection, poly I:C or TBK1 over-expression. When 
probing events of the IRF3 activation pathway, cFLIPL allowed IRF3 phosphorylation 
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and nuclear translocation. However, cFLIPL prevented IRF3-controlled transcription, 
IRF3-promoter interactions, and IRF3-CBP interactions. Co-immunoprecipitation 
analyses showed that cFLIPL interacted with IRF3. Mutational analysis of cFLIPL showed 
that i) IRF3 interactions and ii) cFLIPL nuclear localization are critical for inhibitory 
function. Together, these data suggest that cFLIPL prevents the formation of the IRF3 
enhanceosome, blocking nascent IRF3 transcriptional action.  Unlike other cellular IRF3 
inhibitors, cFLIPL did not degrade or dephosphorylate IRF3. This mechanism is distinct 
from other known cellular IRF3 inhibitors, molecules that act on IRF3 only after IRF3 
has initiated transcription. 
 
2.2  Materials and Methods 
Cell culture  
Human embryonic kidney 293T, mouse embryonic fibroblast (MEFs), the A549 
non-small cell lung cancer cell lines cells, HCT116 colorectal carcinoma cells, and 
AsPC-1 pancreatic adenocarcinoma human cell lines were obtained from the American 
Type Culture Collection. The 293T-TLR3 cell line stably over-expresses the human 
TLR3 gene (Dr. R. Tapping, University of Illinois, Urbana, IL). Cells were cultured in 
appropriate medium supplemented with 10% fetal bovine serum (FBS; Fisher) and 1% 
Penicillin Streptomycin (Fischer). 
Lentivirus infection  
  Control (LL3.7) and shRNA-expressing (shFLIP) lentiviruses were produced by 
co-transfecting 293T cells with packaging plasmids pCMV-dR8.2 (Addgene) and pCMV-
VSV-G (Addgene) and either control plasmid pLL3.7 (Addgene), or pLL3.7-shFLIP 
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(53). At 24 h post-transfection lentiviruses were isolated from cellular supernatants. 
Lentiviruses were concentrated with Lent-X Concentrator (ClonTech). A549 cells were 
infected, and cells were observed for GFP expression as a marker of transduction at 48 h 
pi. Cellular populations with >80% GFP expression were passaged for use as stably 
transduced cell lines to create control (LL3.7) or shFLIP-expressing (shFLIP) A549 cell 
lines.  
Plasmids and transfections 
Plasmid pCI was obtained from Promega. Plasmid MC159 encodes the 
molluscum contagiosum virus MC159L gene (33). Dr. Jeffrey Cohen (National Institutes 
of Health, Bethesda, MD) provided a plasmid encoding a FLAG epitope tagged human 
cFLIPL gene (cFLIPL). Dr. Dongwan Yoo (University of Illinois, Urbana, IL) provided a 
plasmid that encodes the MAVS protein (pMAVS); a plasmid that encodes a 
constitutively active form of IRF3 (pIRF3CA); a plasmid encoding a GFP-IRF3 fusion 
protein (pGFP-IRF3)(33). pTBK1 encodes a FLAG epitope-tagged TBK1 protein and 
was a kind gift from Dr. Siddharth Balachandran (Fox Chase Cancer Center, 
Philadelphia, PA)(33). The FLAG-tagged CBP plasmid (pCBP) was donated by Dr. 
David Lebrun (Queens University, Ontario, CA)(4). Plasmids cFLIPR, DED1, and DED2 
were kind gifts from Dr. Ingo Schmitz (Helmholtz Center for Infection Research, 
Braunschweig, DE) (47). A plasmid encoding the 221 residue cFLIPS was a kind gift 
from Dr. Jae Jung, USC, Los Angeles, CA). It is a FLAG-tagged construct. cFLIPR 
expresses a FLAG-tagged murine cFLIPR. DED1 encodes a myc-tagged DED1 (aa 1-90) 
of cFLIPR.  DED2 expresses a V5 epitope-tagged DED2 (aa 79-186) of cFLIPR.  ΔDED2, 
ΔDED1, and CLD plasmids were kind gifts from Dr. Gerolama Condorelli (University of 
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Naples, Naples, IT)(30). ΔDED2 expresses human cFLIPL aa 1-93 and aa 178-480, while 
ΔDED1 expresses human cFLIPL aa 81-480. CLD expresses human cFLIPL residues 178-
480. ΔDED2, ΔDED1, and CLD express FLAG epitope tagged proteins.  
Plasmid DNA was transfected into cells using TransIT-2020 transfection reagent 
(Mirus Bio) following manufacturer’s protocol. For experiments in which poly I:C 
(Invivogen) was a transfected to stimulate IRF3, 1000 ng of poly I:C was transfected 
using Lipofectamine 2000 (Invitrogen) following manufacturer’s protocol. 
Luciferase assays 
293T, MEFs, or 293T-TLR3 cells were transfected with pIRF3-luc, a plasmid that 
contains a firefly luciferase gene that is under the transcriptional control of four copies of 
the PRDIII promoter sequence specific for IRF3 (33). pRL-null has a sea pansy luciferase 
gene expressed independent of a promoter and is used to assess transfection efficiency. 
Cells were transfected in triplicate with 225 ng pIRF3-luc and 25 ng pRL-null, 1000 ng 
of pCI, MC159, wild-type or mutant cFLIPL-based plasmids and 500 ng pTBK1, or 
pIRF3CA. Cells were lysed at 24 h post-transfection. When poly I:C was used, 293T-
TLR3 cells were transfected as above. At 24 h later, cells were transfected with 1000 ng 
of poly I:C, and cells were lysed 6 hours later.  MVA is an attenuated strain of vaccinia 
virus (3). Transfected cells were infected with MVA at a multiplicity of infection (MOI) 
of 5 PFU/cell in serum-free MEM for 1 h, rocking every 15 min. Virus-containing 
supernatant was removed and replaced with complete medium. At 6 h post-infection, 
cells were lysed. All cells were lysed in 1X PLB (Promega) and luciferase activity was 
detected using the Dual Luciferase Reporter Assay System (Promega), and quantified 
with Clarity Luminescence Microplate Reader (BioTek Instruments). Analysis of firefly 
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and sea pansy luciferase activities was performed as described previously (33). Values 
are shown as mean ± s.d. The Student’s t-test was used to determine the statistical 
significance of inhibition of luciferase activity by wild-type and mutant FLIPs versus 
cells transfected with pCI. Statistically significant inhibition of luciferase activity as 
compared to untreated, pCI-transfected cells is indicated by asterisks (*P < 0.05, ** P < 
0.005). A portion of each lysate was also analyzed for protein expression by 
immunoblotting. 
Quantitative reverse-transcriptase PCR  
293T cells or A549 cell lines stably expressing either the shRNA to cflar 
(shFLIP) or no shRNA (control) were transfected with 1000 ng pCI, pFLAG-cFLIPL, or 
pMC159 in technical triplicates. In some experiments, 293T cells were co-transfected 
with 500 ng pCI or pTBK1 for 24 h.  Alternatively, 24 h post-transfection, A549 cells 
were incubated with 2 µg poly I:C for 6 h. Total RNA was extracted using an RNAeasy 
extraction kit. cDNA was generating using the M-MuLV Reverse Transcriptase (New 
England BioLabs). Quantitative PCR was performed using a Mastercycler realplex EP 
(Eppendorf) and SoFast EvaGreen Super Mix (BioRad) per manufacturer’s instructions. 
The following primers were used: b-actin F (5’-AGTTGCGTTACACCCTTTCT-3’), b-
actin R (5’-ACCTTCACCGTTCCAGTTT-3’), isg15 F (5’- 
CATCTTTGCCAGTACAGGAGCT-3’), isg15 R (5’-ACACCTGGAATTCGTTGCC-
3’). Changes in gene expression level were calculated by the 2
(−ΔΔC(T)) method. Values 
obtained from isg15 cDNA levels were divided by b-actin levels for each sample. For 
normalization, respective b-actin mRNA quantities for each cDNA sample were 
measured, and then each value was normalized to that of unstimulated, pCI-transfected 
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cells, whose value was set to one. For 293T cells, data are presented as the mean +/- s.d. 
from three independent experiments. The Student’s t-test was used to determine 
statistically significant differences in mRNA expression levels. Statistically significant 
inhibition, as compared to untreated pCI-transfected cells, is indicated by asterisks (*P < 
0.05, **P < 0.005).  For A549 cells, statistically significant increases in mRNA when 
cflar is shRNA silenced as compared to cells transduced with empty lentivirus vector, are 
indicated by asterisks (*P < 0.05), using the Student’s t-test. The data are expressed as 
mean +/- s.e.m. using data from three independent experiments. 
Immunoblotting 
For all immunoblots, the protein concentration of lysates was determined by the 
660 nm protein assay (Pierce). An equal amount of protein from each lysate was 
incubated with 5X Non-Reducing Lane Marker (Thermo Scientific) and 5% (vol/vol) 2-
mercaptoethanol (Fisher Scientific) and boiled for 5 min, and then electrophoretically 
separated by SDS-PAGE. Proteins were transferred to polyvinyl difluoride (PVDF) 
membranes (Millipore). Antibody-antigen reactions were detected by using 
chemiluminescence reagents (Amersham and Thermo Scientific) and autoradiography. 
Primary antibodies include: polyclonal rabbit anti-phospho-IRF3 Ser 386 (Millipore), 
monoclonal rabbit anti-IRF3 (Cell Signaling), or monoclonal mouse anti-IRF3 (ab25950; 
abcam), monoclonal mouse anti-FLAG (Sigma-Aldrich), monoclonal mouse anti-E3 (Dr. 
Stuart Isaacs, University of Pennsylvania, Philadelphia), monoclonal mouse anti-TBK1 
(Cell Signaling), monoclonal mouse b-actin (Calbiochem), monoclonal mouse anti-myc 
(Cell Signaling), monoclonal mouse anti-FLIP (7F10; Enzo) or monoclonal rabbit anti-
FLIP (D16A8); Cell Signaling monoclonal mouse anti-V5 (Millipore) and polyclonal 
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rabbit anti-MC159 (42). In some cases, the densities of bands were quantified using 
ImageJ software (1). The values for band intensities for the protein of interest (e.g. IRF3) 
three independent experiments were averaged and compared to loading controls (e.g. 
PARP). Values were normalized to unstimulated, pCI-transfected cells. Data are 
expressed as the mean +/- s.e.m. 
Co-immunoprecipitations  
293T cells were transfected with 500 ng pTBK1, pCI, pGFP-IRF3, pFLAG-CBP, 
and 1000 ng cFLIPL, cFLIPS, or CLD. 24 h later, cells were lysed in DED lysis buffer 
(32). Clarified supernatants were used to assess expression levels of proteins and for co-
immunoprecipitations. For the later, lysates were incubated with anti-FLAG, anti-GFP 
(Santa Cruz), anti-IRF3 or anti-CBP (Cell Signaling) or mouse IgG antibody (Sigma) for 
6 h. Protein G-Sepharose beads (Invitrogen) in a 50% slurry were added to each sample 
and incubation with rotation for 16 h. Beads were collected and washed three times. 
Pelleted beads were suspended in 2x Laemmli buffer containing 5% 2-mercaptoethanol 
and boiled for 5 min. Samples were analyzed for the presence of proteins by using 
immunoblotting.  
A549, HCT116 or AsPC-1 cellular monolayers were either untreated or treated 
with poly I:C (2 micrograms; Sigma) for 6 h.  Cells were collected by trypsinization, 
pelleted by centrifugation, and lysed in DED lysis buffer as above.  Clarified cellular 
lysates were incubated with rabbit anti-IRF3, rabbit anti-FLIP or rabbit IgG antibody 
(Cell Signaling) for 6 h at 4C. Protein G-Sepharose beads (Invitrogen) in a 50% slurry 
were added to each sample and incubation with rotation for 16 h. Beads were collected 
and washed three times. Pelleted beads were suspended in 2x Laemmli buffer containing 
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5% 2-mercaptoethanol and boiled for 5 min. Samples were analyzed for the presence of 
proteins by using immunoblotting, probing immunoblots with antibodies to detect 
endogenous IRF3 (mouse ab25950; abcam) or cFLIPL (mouse 7F10; Enzo). 
Cytoplasmic and nuclear fractionation assay 
293T cells were transfected with either 1000 ng pCI, cFLIPL, cFLIPS, or CLD and 
either 500 ng pTBK1 or pCI. At 24 h later, cells were pelleted, and cytoplasmic and 
nuclear extracts were isolated as described previously (43). Cytoplasmic and nuclear 
extracts were immunoblotted for tubulin (Abcam), PARP (Santa Cruz), IRF3 (Cell 
Signaling), or FLAG-tagged cFLIP constructs (anti-FLAG, Sigma). The values for IRF3 
band intensities for three independent experiments were determined as described above, 
using ImageJ software.  
Chromatin immunoprecipitation (ChIP) 
  ChIP assays were performed according to manufacturer’s instructions (Thermo 
Scientific). Briefly, 293T cells were transfected as described in the co-
immunoprecipitation assays for 24 h.  Cells were cross-linked with 1% formaldehyde 
followed by quenching using 125 mM glycine. Cross-linked chromatin and associated 
proteins were either used as 10% total input or as samples to be immunoprecipitated (IP).  
Samples were incubated with anti-IRF3 (sc-9082-X; Santa Cruz) pre-conjugated to 
provided agarose beads. IPs were reverse cross-linked and genetic material was released 
from the beads by incubation at 65°C. Real-time PCR analyses were performed using the 
recovered DNA and a Mastercycler realplex EP system (Eppendorf). The primers used 
for real-time PCR to quantitate the ChIP-enriched DNA were for ifnb1 (58). Relative 
occupancy values were calculated by determining the apparent IP efficiency (ratios of the 
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final amount of IP DNA as compared to input DNA) and normalized to the level 
observed at a control region in unstimulated, pCI-transfected cells, which was defined as 
1.0. The Student’s T-test was used to determine statistically significant differences in 
DNA levels. Statistically significant inhibition of IRF3 binding activity as compared to 
untreated, pCI-transfected cells is indicated by asterisks (*p< 0.05). 
 
2.3  Results 
cFLIPL inhibits IRF3-controlled transcription of synthetic and natural genes  
  We published that the long isoform of cFLIP (cFLIPL) inhibits IFNb gene 
activation, as measured by an infb1 promoter-controlled luciferase reporter assay (33).  
The infb1 promoter is controlled by NF-kB, AP-1, IRF3, and IRF7, leaving it unclear as 
to which transcription factor(s) is targeted by cFLIPL for this inhibition. cFLIP interacts 
with the IKK complex, an upstream activator of NF-kB (56).  However, cFLIPL retains 
its IFNb inhibitory function in cells deficient for NF-kB (33), ruling out NF-kB.  
A viral homolog of cFLIPL (the molluscum contagiosum virus (MCV) MC159 
protein) inhibits TBK1 activation (33), suggesting that cFLIPL targets IRF3 or IRF7 
activation. IRF3 and IRF7 are each stimulated by known and distinct upstream signal 
transduction pathways (16). However, there are some instances where IRF3 and IRF7 
functions overlap, which could complicate the studies with cFLIPL. To overcome this 
issue, we used an IRF3-controlled firefly luciferase reporter construct, which allows for 
the measurement of IRF3 activation alone (Figure 2.1). Several viruses stimulate IRF3 
activation during infection (14). For example, MVA is an attenuated vaccinia virus that 
activates the interferon response in MEFs (52). However, IRF3 activation was blocked in 
62	  	  
MEFs over-expressing cFLIPL or MC159 as measured by reporter assays (Figure 2.1A). 
MVA-induced IFNb production is due, in part, to PKR sensing of viral dsRNA (52). We 
repeated experiments using poly I:C, an IRF3-stimulating agent that stimulates TBK1 
activation via RIG-I, MDA-5 and TLR3 (2, 19). Because 293T cells do not express high 
levels of TLR3, a 293T cell line stably over-expressing TLR3 (293T-TLR3) was used to 
ensure robust IRF3 signaling upon incubation with poly I:C. The 293T-based cell line 
was used because of its high transfection efficiency rate and its common use in studying 
IRF activation pathways (33, 49, 57, 59). cFLIPL, like MC159, also inhibited IRF3-
controlled luciferase activity under this condition (Figure 2.1B), suggesting cFLIPL 
targeted a downstream signaling event shared by MVA infection and poly I:C treatment. 
In support of this, we observed that cFLIPL inhibited IRF3 activation when TBK1 over-
expression stimulated IRF3 activation (Figure 2.1C), and this inhibition was greater than 
that observed with MC159 and this inhibition was shown to be dose dependent (Figure 
2.1D). For this set of experiments, regular 293T cell lines that do not over-express TLR3 
were used. This suggested that cFLIPL acted on an event occurring at or downstream of 
TBK1.  
  We evaluated the expression of IRF3-controlled genes as a second independent 
means to detect cFLIPL action.  We examined the transcription of two cellular genes, 
isg15 and isg54/IFIT2 (Figure 2.1E and 2.1F) that are regulated by IRF3 (12) by using 
RT-qPCR. In this case, TBK1 over-expression was used to stimulate IRF3, as evidenced 
by the transcription of isg15 and isg54 (Figure 2.1E and 2.1F). In contrast, cFLIPL 
expression reduced isg15 and isg54 gene transcription as compared to vector-transfected 
cells. The transcription of both ISGs was reduced in MC159-expressing cells, and this 
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was expected since MC159 inhibits TBK1 activation (33).  Together, data shown in 
Figure 2.1 supported the model that cFLIPL antagonizes the IRF3 activation pathway. 
cFLIPL inhibits an event downstream of IRF3 phosphorylation 
The next goal was to identify the cFLIPL molecular mechanism of inhibition. One 
obvious possibility was that cFLIPL would act similar to its MC159 homolog, by binding 
to and inhibiting TBK1 activation (33). However, two pieces of data in Figure 2.2 
showed that cFLIPL used a different mechanism. First, cFLIPL inhibited IRF3 activation 
triggered by over-expression of a constitutively active phospho-mimetic form of IRF3 
(pIRF3CA) (Figure 2.2A). MC159 cannot inhibit this because IRF3 activation occurs 
downstream of TBK1 activation (14, 16, 21). Second, cFLIPL did not prevent IRF3 
phosphorylation (Figure 2.2B). Figure 2.2B shows that MC159 prevented TBK1-induced 
IRF3 activation, as measured by a decrease in the intensity of the phospho-IRF3-
containing band (Figure 2.2C). However, there was no observable difference in phospho-
IRF3 levels in cFLIPL versus vector-expressing cells (Figure 2.2B and 2.2C).  
Several other cellular proteins down-regulate IRF3 activation (22, 25, 49, 57). 
Most target the transcriptionally active form of IRF3, modifying IRF3 such that it is 
degraded by the cellular proteosomal machinery. Importantly, IRF3 protein levels 
remained consistent in the presence of cFLIPL (Figure 2.2). These data suggest that 
cFLIPL has a mechanism to inhibit IRF3 that is distinct from other known cellular IRF3 




The caspase-like domain (CLD) of cFLIPL is necessary and sufficient to inhibit IRF3 
activation 
There are three detectable splice variants of cFLIP: cFLIPL (55 kDa), cFLIP short 
(cFLIPS; 24 kDa), and cFLIP raji (cFLIPR; 24 kDa)(10, 17, 40). These are depicted in 
Figure 2.3A. Each variant contains two death effector domains (DEDs), which are death 
fold motifs present in the cellular apoptotic FADD and procaspase-8 proteins (48, 56).  
However, cFLIPL alone possesses an additional C-terminal region that is 302 amino acids 
in length (Figure 2.3A).  While this region shares some homology to the procaspase-8 
caspase domain, the cFLIPL caspase-like domain (CLD) lacks caspase activity because 
there are several amino acid substitutions in the region required for caspase activity (17). 
The C-terminal region also possesses nuclear localization sequences (NLS) at residues 
435-437 and 472-474 (18).   
Luciferase reporter assays were used to identify the cFLIP region that controls 
IRF3 activation, using TBK1 over-expression to trigger IRF3 activation (Figure 2.3). 
Figure 2.3B uses mutants in the cFLIPL background. In contrast, mutants DED1 and 
DED2 were in the cFLIPR background in Figure 2.3C.  Thus, cFLIPR was used as a 
control for this set of experiments. Interestingly, Figure 2.3B showed that either DED 
was dispensable for IRF3 activation because mutant cFLIPL that lacked either DED1 
(DDED1) or DED2 (DDED2) still inhibited IRF3 activation. Expression of the CLD-
containing C-terminus (CLD; amino acids 178-480) inhibited IRF3 activation, indicating 
this region was sufficient for the inhibitory phenotype (Figure 2.3B). Interestingly, 
cFLIPR, or constructs expressing only DED1 or DED2 provided no IRF3 inhibitory 
function (Figure 2.3C). Because cFLIPR is 74% similar to cFLIPS  (27), cFLIPS is not 
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expected to inhibit IRF3 activation. Indeed, data in Figure 2.6 showed that cFLIPS did not 
inhibit IRF3-induced luciferase activity (Figure 2.6B).  Thus, the cFLIP DEDs 
themselves are not sufficient to inhibit IRF3 activity. Together, these data mapped the 
IRF3 inhibitory region of cFLIPL to residues 222-480.  Nearly identical results were 
observed if over-expression of MAVS (instead of TBK1) was used to trigger IRF3 
activation (Figure 2. 4).  
cFLIPL does not inhibit IRF3 nuclear translocation and is present in the nucleus  
A majority of inactive IRF3 resides in the cytoplasm but the inactive form of 
IRF3 can cycle between the cytoplasm and nucleus (20). Regardless, the phospho-IRF3 
dimer translocates to the nucleus due to an NLS present in IRF3 (23, 55). Thus, a next 
step was to query if cFLIPL prevented IRF3 nuclear translocation. Cellular fractionation 
assays were used for this purpose because they are sensitive enough to detect IRF3 
nuclear translocation.  For example, there was a visible increase in IRF3 protein levels in 
the nuclear extracts of TBK1 over-expressing cells versus vector-transfected cells (Figure 
2.5). Note that a small amount of IRF3 was detected in nuclei of unstimulated cells, 
probably reflecting IRF3 shuttling between the cytoplasm and nucleus (60). Interestingly, 
a similar trend was observed when cells expressed wild-type cFLIPL: there were no visual 
differences in nuclearly localized IRF3 in unstimulated versus stimulated cells.  This 
remained true for cells expressing a mutant of cFLIPL (CLD) that inhibited IRF3 
activation, and for cells expressing cFLIPS, a protein that did not inhibit IRF3 activation. 
Similar to Figure 2.2B, IRF3 protein levels remained similar under all conditions tested. 
Thus, cFLIPL does not prevent IRF3 nuclear translocation. It was observed that the 
nuclear IRF3 protein levels were higher in unstimulated cells that were co-transfected 
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with a cFLIPL- and cFLIPS-expressing cells than in pCI-or CLD-transfected cells. The 
reasons for this pattern are not clear to us currently, but these data suggest that the DED 
regions of cFLIP act on other signaling pathways that may indirectly trigger IRF3 nuclear 
translocation.  At least for cFLIPL, this nuclear IRF3 is probably not phosphorylated due 
to data shown in Figure 2.2B. When the density of IRF3-containing bands from nuclear 
extracts was quantified using ImageJ software (Figure 2.5B right panel), it was 
determined that IRF3 nuclear translocation was not significantly inhibited by the 
presence of cFLIP constructs.   
The localization of cFLIP also was examined in these same extracts to gain a 
greater understanding of how cFLIPL may inhibit IRF3 activation.  cFLIPL is often 
regarded as a cytoplasmic protein because it interacts with other cytoplasmic proteins 
including procaspase-8 (56).  However, the cFLIPL C-terminus possesses two NLS’s and 
it has been shown that cFLIPL is present in the nucleus (18).  Thus, it was not surprising 
to detect wild-type cFLIPL or mutant CLD protein in the nucleus and cytoplasm (Figure 
2.5). The NLS sequences are absent in cFLIPS and this isoform was detected only in the 
cytoplasm, as would be expected (Figure 2.5).  Tubulin proteins were detected solely in 
the cytoplasm and PARP proteins were detected solely in the nuclear extracts, showing 
the successful separation of cellular compartments. 
cFLIPL prevents the IRF3 transcription factor from binding to its target promoter site 
Nuclear IRF3 binds to DNA sequences in promoters of its target genes via its 
DNA binding domain (DBD) (23, 46). A chromatin immunoprecipitation (ChIP) assay 
was used to examine the extent of IRF3 interactions with the IFNb promoter in cells 
expressing wild-type or mutant cFLIP proteins (Figure 2.6A). IRF3 was 
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immunoprecipitated from unstimulated and stimulated cells, and IRF3-IFNb promoter 
interactions were assessed by using qPCR. As expected, the IFNb promoter was PCR 
amplified in TBK1 over-expressing cells, indicating that IRF3 successfully bound to the 
IFNb promoter (Figure 2.6A). In contrast, IRF3-promoter interactions significantly 
decreased in cFLIPL-expressing cells (Figure 2.6A). Note that both the cFLIPR and 
cFLIPS proteins have nearly identical phenotypes; neither inhibit IRF3-controlled 
luciferase activity (Figure 2.6B and 2.3C).  Finally, the CLD construct prevented IRF3-
DNA interactions (Figure 2.6A), correlating with its ability to inhibit IRF3-based 
luciferase activity (Figure 2.3). 
cFLIPL interacts with IRF3 and this interaction correlates with a loss of IRF3-CBP 
interactions and a loss of IRF3 inhibition 
cFLIPL and CLD were the only molecules that inhibited IRF3 activation (Figure 
2.3), were present in the nucleus (Figure 2.5), and prevented IRF3-DNA interactions 
(Figure 2.6).  Based on these data, a reasonable hypothesis is that the nuclear-localized 
cFLIPL interacts with nuclear lRF3 to prevent formation of an IRF3 enhanceosome. This 
was tested using co-immunoprecipitation assays to detect IRF3-cFLIPL interactions 
(Figure 2.7). Cells were co-transfected to express an IRF3-GFP fusion protein, CBP and 
wild-type or mutant cFLIPL proteins. In some cases, cells were co-transfected pTBK1 to 
activate IRF3. As expected, IRF3-CBP interactions were detected under conditions where 
IRF3 was activated (Figure 2.7).  However, these interactions were disrupted by cFLIPL. 
Since this was concomitant with the presence of cFLIPL in the immunoprecipitates 
(Figure 2.7A) it was likely that cFLIPL interacted with IRF3.  Similarly, CLD co-
immunoprecipitated with IRF3, and IRF3 no longer interacted with CBP in these same 
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reactions. In contrast, no interactions were detected between IRF3 and cFLIPS, and IRF3-
CBP interactions were retained in the presence of cFLIPS. All cells expressed similar 
amounts of IRF3-GFP, CBP or cFLIP (Figure 2.7B). Figure 2.7C used IgG instead of 
anti-GFP for immunoprecipitations to show no non-specific binding of our proteins of 
interest to protein G-sepharose beads.  
Similar experiments were performed to ask if endogenous IRF3 had the same 
binding properties as GFP-IRF3 (Figure 2.8A). We observed that wild-type cFLIPL and 
CLD co-immunoprecipitated with endogenous IRF3. As in Figure 2.7, these interactions 
only occurred under conditions known to activate IRF3.  We did not detect cFLIPS-IRF3 
interactions under any condition tested. A reverse co-immunoprecipitation showed that 
endogenous IRF3 interacted with the cFLIPL and CLD proteins but not cFLIPS (Figure 
2.8B).  In this case, ectopic MAVS expression was used as an alternative mechanism to 
trigger IRF3 activation. IRF3 protein expression remained stable regardless of the 
presence of wild-type or mutant cFLIP constructs (Figs. 2.8C and 2.8D).  These 
interactions between IRF3 and cFLIP were specific because neither IRF3 nor cFLIP was 
immunoprecipitated when a non-specific IgG was used instead of anti-IRF3 (Figure 2.8E) 
or anti-FLAG (Figure 2.8F). 
The role of cFLIPL in preventing IRF3 activation in cancer cell lines 
There are many primary cancers, like non-small cell lung cancer (NSCLC), 
pancreatic cancer, and colorectal cancers, where there is a correlation between a decrease 
in in ifnb1, and/or isg54 gene transcription (genes controlled by IRF3) and an increase in 
cflar transcription (the gene that encodes cFLIPL) as identified by using Oncomine (34). 
These data suggest that cFLIPL may bind to and inhibit IRF3 in tumor cells as a means to 
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prevent IRF3-induced transcription of immune genes. To test this hypothesis, the NSCLC 
A549 cell line, HCT116 colorectal carcinoma cell line, and the AsPC-1 pancreatic 
adenocarcinoma cell lines were used. Unlike the 293T cell line used above, A549 cells, 
HCT116 cells, and AsPC-1 cells express detectable levels of endogenous cFLIPL, 
allowing us to examine cFLIPL-IRF3 interactions under conditions in which neither 
protein must be ectopically expressed (35, 49). Figure 2.8A showed that cFLIPL co-
immunoprecipitated with IRF3 in all three of the cell lines examined. This interaction 
was observed at low levels in unstimulated cells, and greatly increased when cells were 
stimulated with poly I:C. When examining the lysates from these samples, it was noted 
that IRF3 and cFLIPL levels were present in similar amounts. The cFLIP-IRF3 
interactions were specific because these interactions were not observed if an IgG isotype 
control antibody was used in co-immunoprecipitations in place of anti-IRF3 or anti-FLIP. 
If cFLIPL is indeed responsible for IRF3 inhibition in various cancers, then a lack 
of cFLIPL would render these cells susceptible to IRF3 activation. To test this hypothesis, 
we further examined the A549 cell line and stably transduce them with a lentivirus 
construct that encodes a silencing hairpin RNA specific for cflar (the gene encoding 
cFLIP; shFLIP). A second set of A549 cells was transduced in parallel with a lentivirus 
that does not encode shRNA (control) (53). Figure 2.9B shows cFLIPL protein levels 
were decreased only when A549 cells were transduced with a lentivirus containing the 
shRNA to cflar (shFLIP). In contrast, cFLIPL levels were similar in cells that were not 
transduced (mock) or transduced with a lentivirus that lacks shRNA (control). When 
transduced cells were incubated with poly I:C to stimulate IRF3, there was statistically 
significant increase in the transcription of two genes known to be controlled by IRF3 -- 
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isg15 (Figure 2.9C) and isg54 (Figure 2.9D) -- when cFLIPL protein levels were 
decreased versus conditions in which cFLIPL protein levels were unchanged from mock-
transduced cells. Thus, IRF3 activation is indeed dampened by cFLIPL in this cell line. 
 
2.4  Discussion  
The IRF3 transcription factor is very important for the expression of type I IFN 
and ISGs (16, 45). Data here are the first to report how cFLIPL controls IRF3 activation 
on a molecular level. In summary, cFLIPL inhibited the transcription of cellular and 
synthetic genes regulated by promoters containing known IRF3 binding sites.  This 
phenotype was observed in different cell lines and under several conditions that stimulate 
IRF3. Following the well-known steps of the IRF3 activation pathway, cFLIPL allowed 
upstream signaling events including IRF3 nuclear translocation. However, cFLIPL 
inhibited IRF3 from interacting with its DNA promoter and with CBP.  This function 
mapped to the nuclearly localized C-terminal region of cFLIPL. The current model based 
on these data is that cFLIPL inhibit the formation of an IRF3-based enhanceosome.  There 
are several remaining questions to be asked, including if cFLIPL-IRF3 interactions 
initially occur in the cytoplasm or in the nucleus. This is currently under investigation in 
our lab. IRF3 is shuttled from the nucleus to the cytoplasm due to the presence of NLSs 
and NESs (60). Here, we find that cFLIPL inhibits the action of a dimerized phospho-
mimetic form of IRF3 (IRF3CA) (Figure 2.2A). cFLIPL also is present in the cytoplasm 
and nucleus (Figure 2.5A). This would suggest that cFLIPL preferentially binds to a 
dimeric IRF3 complex, and may bind to these dimers regardless of whether they are in 
the cytoplasm or nucleus.  
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There are other cellular proteins known to inhibit IRF3 function. These proteins 
target the transcriptionally active form of IRF3. For example, the RTA-associated 
ubiquitin ligase (RAUL) promotes ubiquitin-mediated degradation of IRF3 (57) as a 
means of halting IRF3-controlled gene transcription. Protein phosphatase A2 (PPA2) 
dephosphorylates the activated form of IRF3, which decreases IRF3 transcriptional 
activity (25).  However, neither unmodified nor phospho-IRF3 levels were reduced in the 
presence of cFLIPL in the system used here. This implies that cFLIPL acts prior to the 
above-listed cellular inhibitors, and prevents IRF3-controlled transcription from initiating 
in the first place.  As such, cFLIPL may represent a cellular mechanism to prevent low-
level or “background” IRF3 activation.  Alternatively, cFLIPL may bind to IRF3 to block 
post-translational modifications (e.g., ubiquitination) of IRF3. In this case, cFLIPL would 
allow IRF3 to be returned to the cytoplasm for future use. Future studies will examine 
these possibilities to better understand this new cellular mechanism to down-regulate 
IRF3 activity. 
cFLIPL is a member of the FLIP family, which defined by proteins that possess 
two tandem DEDs (48, 56).  This family includes proteins encoded by the molluscum 
contagiosum poxvirus (MC159 and MC160) and the Kaposi’s sarcoma herpesvirus 
(K13). Viruses encode proteins to inhibit IRF3 as a common strategy to fight the anti-
viral immune response (21, 44). Both MC159 and MC160 inhibit IRF3 activation, but use 
mechanisms distinct from cFLIPL. For example, MC159 binds to and inhibits TBK1 
activation (33). Moreover, the MC159 DEDs are important for TBK1 binding and 
subsequent IRF3 inhibition (33). In contrast, the cFLIPL DEDs are dispensable for IRF3 
activation in the system used here. The MC159 and cFLIPL DEDs share approximately 
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30% sequence homology. Therefore, there may be sufficient differences between these 
DEDs that are responsible for these differences in function. The K13 role in IRF3 
regulation remains unclear. K13 induces IFNb production (26), implying that K13 may 
activate IRF3. However, this phenotype may be due to the NF-kB activating function of 
K13 (24). Another approach to examine K13 regulation of IRF3 in an NF-kB-
independent manner used p65 -/- MEFs (21). In these conditions, K13 does not stimulate 
IFNb activation (as examined by a reporter assay) and weakly inhibits inhibit MAVS-
induced IRF3 activation as compared to other FLIPs (33). It is intriguing that these 
cellular and viral homologs have distinct biochemical and biological properties with 
regard to IRF3 regulation.  These differences give scientists a unique set of reagents to 
more deeply understand how to manipulate aspects of the IRF3 activation pathway to the 
benefit of cellular and organismal health. 
cFLIPL is a multi-functional protein, regulating events including apoptosis, NF-
kB, ERK activation, autophagy, necroptosis and Wnt signaling (9, 37). It also has myriad 
cellular biding partners including procaspase-8, Ku70, TRAF2 and RIP1 (37).  This 
raised the concern that this newly identified function of cFLIPL is indirect.  For example, 
since caspase-8 cleavage of RIP1 kinase down-regulates IRF3 activation, one worry is 
that cFLIPL may simply be inhibiting caspase-8 activation to indirectly inhibit the signal 
transduction pathway leading from MAVS to IRF3 activation (31). Several pieces of data 
diminish this possibility. Most importantly, we observed that cFLIPL co-
immunoprecipitated with IRF3, which suggests that cFLIPL functions directly on the 
IRF3 signal transduction pathway.  Second, in our system, cFLIPL inhibited IRF3 
activation in a caspase-8-independent manner (Figure 2.10).  Third, we observe a 
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correlation between cFLIPL interactions with IRF3 binding and inhibition of IRF3 
activation, when using large deletion mutants of FLIP. 
Only a few publications have examined the relationship between cFLIPL and type 
I IFN production.  Two publications report data that complement the findings described 
here (13, 33).  However, Buskiewicz et al. report an opposing function: cFLIPL increases 
IFNb production triggered by coxsackievirus B3 (CVB3) infection (37). Potential reasons 
for these differences are the different stimuli used in those studies. We observed that 
cFLIPL inhibits IRF3 activation triggered by a DNA virus or by poly I:C (a reagent that 
uses TLR3 and does not trigger MAVS-induced IRF3 activation).  Buskiewicz et al. used 
an RNA virus for infection, which is known to trigger MAVS-induced IRF3 activation 
(6).  Perhaps the differences we observe reflect different PRR-based signal transduction 
pathways triggered by RNA versus DNA viruses. Additionally, this phenotype may be 
cell type specific. For example, we show that caspase-8 is dispensable for IRF3 activation 
in the 293T cell line used here.  However, caspase-8 is required to stimulate IRF3 
activation in the cFLIPL-expressing MEF cells (6). The ratio of cFLIPL to procaspase-8 
dictates whether cFLIPL has pro- or anti-apoptotic function (7, 9).  Thus, another 
possibility is that the cellular concentrations of cFLIPL dictate its effect on IRF3. 
Regardless, the continued study of cFLIPL and IRF3 is critical for a deeper understanding 
of conditions that allow cFLIPL to inhibit or activate type I IFN production.  
  This study identifies a molecular mechanism for cFLIPL. This finding impacts 
several scientific disciplines. For cancer, in silico analysis identified a statistically 
significant relationship between an upregulation of cFLIP gene (cflar) and a down-
regulation of the isg54 gene (a gene whose expression is controlled solely by IRF3) in 
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non-small cell lung carcinoma (P = 0.0053), pancreatic carcinomas (P = 0.021) and 
angioblastic T-cell lymphomas (P = 0.002) and colorectal adenocarcinoma (P = 
0.0000000057) as determined by Oncomine (34). This implies that some cancer cells may 
have an increased level of cFLIPL to inhibit type I IFN production as an immune evasion 
strategy. In support of this model are our data with the A549 cell line, a model cell line 
for non-small cell lung carcinomas, shown here (Figure 2.9). One prediction is that 
disruption of cFLIPL inhibitory function in these cancers would increase immune 
responses, perhaps halting tumorigenesis. Type I IFN production is also associated with 
several autoimmune diseases (36). Interestingly, IRF3 itself may be responsible for some 
of the disease observed with systemic lupus erythematosus (38). A next step is to ask if 
cFLIPL, or a cFLIPL mimetic, can be used as a strategy to diminish the severity or onset 
of autoimmune diseases. Rapid type I IFN production is a hallmark of acute virus 
infection (1). Interestingly, type I IFN production also helps establish persistent virus 
infections (29). Thus, it will be of great interest to infectious disease experts to 
understand how cFLIPL regulation of IRF3 affects acute versus chronic virus infections 









2.5 Figures  
 
Figure 2.1 cFLIPL inhibits IRF3-controlled luciferase activity. Luciferase activity in 
(A) MEF or (B) 293T-TLR3 or (C-D) 293T cells transiently co-transfected for 24 hours 
with luciferase reporter plasmids (pIRF3-luc, pRL-null) and 1000 ng control plasmid 
(pCI) or plasmids encoding cFLIPL or MC159. (A) Cells were either mock-infected or 
infected with MVA (MOI = 5 PFU/cell) or (B) incubated with 1000 ng of poly I:C or (C 
and D) co-transfected with pTBK1. Cells were lysed at (A and B) 6 h or (C and D) 24 h 
later. Results are shown as fold-induction of luciferase activity, relative to those of pCI-
transfected cells.  Immunoblot analysis of lysates also was performed. (E and F) 
Quantitative RT-PCR (qPCR) analysis of (E) isg15 and (F) isg54 mRNA from 293T cells 
co-transfected with pTBK1 and 1000 ng control plasmid (pCI) or plasmids encoding 
cFLIPL or MC159 for 24 h. Results are presented as isg15 and isg54 mRNA relative to  -
actin mRNA expression for each sample, and recorded as relative to those of cells 
transfected with empty vector (pCI). *P < 0.05, compared with cells transfected with 
empty vector. All experiments were performed at least three times, and data are 
expressed as the mean +/- s.d. 
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Figure 2.2 cFLIPL does not inhibit IRF3 phosphorylation.  Luciferase activity in 293T 
cells transiently co-transfected for 24 hours with luciferase reporter plasmids, 500 ng 
pIRF3CA and 1000 ng cFLIPL or MC159. Results are presented as fold-induction of 
luciferase activity relative to those of cells transfected with empty vector (pCI).  * P < 
0.05 compared with cells transfected with empty vector.  Immunoblot analysis of lysates 
also was performed. (B) Cells were transfected with 500 ng pTBK1 or pCI and 1000 ng 
pCI, pCI, cFLIPL or MC159 for 24 h.  Protein expression from cellular lysates was 
evaluated by immunoblotting.  (C) The intensity of the phospho-IRF3-containing bands 
(p-IRF3) from three independent experiments were evaluated using ImageJ software. The 
density of a phospho-IRF3-containing band was divided by the intensity of the  -actin 
containing band. The relative fold change in phospho-IRF3 was determined by 
normalizing the ratio of phospho-IRF3/b-actin to that of pCI-transfected cells, whose 
value was set to one.  Data are expressed at the mean +/- s.e.m. 
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Figure 2.3 Analysis of cFLIP constructs for ability to inhibit of IRF3-controlled 
luciferase activity. (A) A schematic of cFLIP constructs used for luciferase activity 
assays. The tandem death effector domains (DEDs) are denoted as DED1 and DED2.  
The two nuclear localization signals (NLS) in the C-terminal region of cFLIPL are shown. 
(B and C) Luciferase reporter assays in 293T cells transiently co-transfected with 
luciferase reporter plasmids (pIRF3-luc and pRL-null), pTBK1 and wild-type or mutant 
(B) cFLIPL or (C) cFLIPR plasmids.  At 24 h later, cells were analyzed for luciferase 
activities as described in Figure 2.1. * P < 0.05, compared with cells transfected with 
empty vector (Student's t-test).  Immunoblot analysis of cellular lysates for cFLIP protein 





Figure 2.4 Mutational analysis of cFLIPL and inhibition of IRF3-controlled 
luciferase activity. (A) Luciferase reporter assays in 293T cells transiently co-transfected 
with combinations of plasmids containing wild-type or mutant cFLIP-based constructs 
(DDED1, DDED2, or CLD) and empty vector (pCI) or pMAVS for 24 h. * P < 0.05, 
compared with cells transfected with empty vector (Student's t-test).  Immunoblot 
analysis of cellular lysates for cFLIP protein expression also was performed. (B) 
Luciferase reporter assays in 293T cells transiently co-transfected with combinations of 
plasmids containing wild-type or mutant cFLIP-based constructs (cFLIPL, cFLIPR, DED1, 
or DED2) and empty vector (pCI) or pMAVS for 24 h. * P < 0.05, compared with cells 
transfected with empty vector (Student's t-test).  Immunoblot analysis of cellular lysates 




Figure 2.5 cFLIPL does not inhibit IRF3 nuclear translocation. (A) 293T cells were 
co-transfected for 24 h with cFLIP-based plasmids (1000 ng) and pTBK1 (500 ng) or pCI 
(500 ng).  Cells were lysed and cytoplasmic and nuclear proteins were extracted, and 
samples were probed for the indicated proteins by immunoblotting. b-tubulin and PARP 
serve as markers of cytoplasmic content and nuclear content, respectively. (B) A 
graphical representation of the density of IRF3-containing bands in relation to tubulin 
(cytoplasmic fractions) or PARP (nuclear extracts) from 3 independent experiments. The 
values for IRF3-, tubulin- or PARP-containing band intensities were determined using 
ImageJ software, averaged and normalized to untreated, pCI-transfected cells for either 
















Figure 2.6 cFLIPL, but not cFLIPS, prevents IRF3 recruitment to the IFN  
promoter. (A) ChIP assay to detect IRF3 binding to the IFN  promoter. 293T cells were 
transfected with 500 ng pTBK1 or pCI and 1000 ng of plasmids encoding cFLIP proteins 
for 24 h. Results are presented as IFN  values of immunoprecipitated DNA to total input 
DNA for each experimental sample.  (B) 293T cells were transfected as described in 
Figure 2.1C, substituting a plasmid encoding cFLIPS for MC159. For both assays, values 
were expressed as the mean +/- s.d.  Values were normalized to unstimulated, pCI-





Figure 2.7 The CLD of cFLIPL is sufficient and necessary to co-immunoprecipitate 
with IRF3 and to prevent CBP-IRF3 interactions. Immunoblot (IB) analysis of (A) 
GFP-IRF3 fusion protein immunoprecipitated (IP) from 293T cells co-transfected with 
pGFP-IRF3 (500 ng), pCBP (500 ng) and various combinations of pCI, pTBK1 and 
FLAG-tagged cFLIP proteins. Anti-GFP was used as the antibody in these IPs. IP 
samples were probed for the presence of CBP and FLAG-tagged FLIP proteins by 
immunoblotting (IB). (B) A portion of each lysate prior to immunoprecipitation was set 
aside as input sample, and immunoblotted to detect protein expression. (C) IB analysis of 
proteins IP-ed from cellular lysates with non-specific IgG instead of anti-GFP.  All 




Figure 2.8 Endogenous IRF3 interacts with cFLIPL and the CLD, but not cFLIPS. 
Immunoblot (IB) analysis of an immunoprecipitated (IP) endogenous IRF3 from 293T 
cells co-transfected with plasmids encoding FLAG-tagged cFLIP proteins and various 
combinations of pCI and pTBK1 or pMAVS. (A) Cellular lysates were IP-ed with (A) 
anti-IRF3 or (B) anti-FLAG antibodies and IP-ed  samples were probed for the presence 
of IRF3 and FLAG-tagged FLIP proteins by immunoblotting. (C and D) A portion of 
each lysate prior to immunoprecipitation was set aside as input sample, and 
immunoblotted to detect protein expression. (E and F) IB analysis of proteins IP-ed with 
non-specific IgG instead of anti-IRF3 or anti-FLAG. All experiments were performed at 

















Figure 2.9 Endogenous cFLIPL-IRF3 interactions and IRF3-controlled isg gene 
expression in A549 cells. (A) A549, HCT116, and AsPC-1 cells were unstimulated or 
stimulated with 2 micrograms poly I:C for 6 h. Clarified cellular lysates were 
immunoprecipitated with anti-IRF3, anti-FLIP or IgG antibodies. Immunoprecipitates 
were probed for the presence of endogenous IRF3 and cFLIPL proteins by 
immunoblotting.  A portion of each lysate prior to immunoprecipitation was set aside as 
input sample, and immunoblotted to detect protein expression.  (B) Immunoblot analysis 
of cFLIP levels in mock-infected A549 cells or A549 cells transduced with a lentivirus 
expressing (shFLIP) or not expressing (control) shRNA specific for cFLIP (shFLIP). (C 
and D) Quantitative RT-PCR (qPCR) analysis of isg15 and isg54  mRNA from 
transduced A549 cells from Figure 2.9B. Cells were either unstimulated (NS) or 
incubated with 2 micrograms poly I:C for 6 h. Results are presented as the mean +/- 
s.e.m. of isg15 and isg54 mRNA relative to  -actin mRNA expression for each sample 
for three independent experiments, and recorded as relative to those of cells transfected 










Figure 2.10 cFLIPL inhibits IRF3 activation independent of caspase-8 activation. (A) 
Immunoblot analysis of the zymogenic (52 kDa) and active (12 kDa) forms of caspase-8 
assessed by SDS-PAGE.  293T cells were incubated in regular medium or medium 
containing 50  M with z-IETD-fmk for 30 min prior to addition of regular medium or 
medium containing TNF and cycloheximide (CHX). (B)  Luciferase activity in 293T 
cells transiently co-transfected for 24 hours with luciferase reporter plasmids and 
combinations of control plasmid (pCI) or plasmids encoding TBK1 (pTBK1) or cFLIPL. 
In some cases, cells were incubated in medium containing z-IETD-fmk.  Results are 
presented as fold-induction of luciferase activity, presented relative to those of cells 
transfected with empty vector (pCI) and incubated in regular medium.  * P < 0.05 and ** 
P < 0.005, compared with cells transfected with empty vector (Student's t-test).  
Immunoblot analysis of cellular lysates for cFLIPL and TBK1 protein expression also was 
performed. (C) IRF3-controlled luciferase activity in 293T cells transiently co-transfected 
for 24 hours with a plasmid expressing a dominant-negative form of procaspase-8 
(pC360S) and co-transfected with combinations of pCI, pTBK1 and cFLIPL.  Results are 
presented as fold-induction of luciferase activity, presented relative to those of cells 
transfected with empty vector (pCI).  *P < 0.05 and **P < 0.005, compared with cells 
transfected with empty vector (Student's t-test).  Immunoblot analysis of cellular lysates 
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  Type I interferons (IFN) are comprised of IFNa and IFNa, and their production is 
the first line of defense against virus infection (17). IFNa represents a group of cytokines 
(e.g., IFNa4 and IFNa6) that are predominately regulated by the interferon regulatory 
factor 7 (IRF7) transcription factor (19, 20, 29). In most cell types, IRF7 is expressed in 
low levels. However, IRF7 is expressed at high levels in hematopoietic cells like 
plasmacytoid dendritic cells (pDCs) (23, 47). IFNa production is increased in a variety of 
autoimmune diseases, including systemic lupus erythematosus (SLE), Sjogren’s 
Syndrome (10), type I diabetes (1), rheumatoid arthritis (RA) (14), and others (38, 68). 
This exemplifies that the precise up- and down- regulation of IFNa production is critical 
for proper immune system homeostasis.  
IRF7 activation is required for robust IFNa expression (20). IRF7 activation 
occurs via the engagement of endosomal nucleic acid sensors (e.g., TLR7, TLR8 and 
TLR9) (Figure 3.1). TLR9 homodimers are activated upon binding of viral (27) or 
bacterial unmethylated CpG motifs (e.g., CpG-A) (9) or DNAs involved in autoreactive 
immune complexes (43, 52). In all cases, the MyD88 protein is recruited to the 
cytoplasmic portion of these TLRs (25), acting as a critical signal adaptor molecule 
(Figure 3.1). Next is the assembly of a dynamic complex including at least IRAK1, 
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IRAK4 (54), and TRAF6 (25). IKKa is subsequently recruited and activated, either by 
IRAK1 (12), or an unknown kinase (19, 21). Regardless, IKKa goes on to phosphorylate 
IRF7, while TRAF6 K63-linked polyubiquitinates IRF7(25, 54). Phospho-IRF7 then 
homodimerizes (35) and translocates to the nucleus, where it drives expression of IFNa 
genes as well as other interferon stimulated genes (ISGs)(19).  
Because IFNa has powerful pro-inflammatory properties, cells have mechanisms 
to down-regulate IFNa production in the absence of virus infection. For example, RAUL 
is an E3 ligase that promotes IRF7 K48-linked polyubiquitination and degradation (64). 
PP2A is a dephosphorylase that inactivates IRF7 (32). In contrast, 4E-BP1/2 inhibits 
IRF7 translation (8). The cellular aryl hydrocarbon receptor interacting protein (AIP) 
inhibits IRF7 action downstream of IRF7 phosphorylation; it inhibits nuclear 
translocation of IRF7 homodimers (67). 
The cellular FLICE-inhibitory protein (cFLIP) was originally identified as an 
inhibitor of extrinsic apoptosis (22). There are two major isoforms of cFLIP, the long 
isoform (cFLIPL) and a shorter splice variant (cFLIPS), and both are members of the 
FLICE-like inhibitory protein (FLIP) family (56). Our group recently identified that 
cFLIPL is an IRF3 antagonist; cFLIPL binds to IRF3 to prevent enhanceosome formation 
(13). IRF3 demonstrates considerable sequence homology to IRF7 (65), begging the 
question if cFLIPL may bind to and antagonize IRF7 to control IFNa production. In 
support of this hypothesis is one report showing that over-expression of cFLIPS correlates 
with a decrease in IFNa protein expression (4). To answer this question, we examined 
the effect of cFLIP on different steps of the TLR9-induced IRF7 activation pathway, 
using CpG-A to specifically trigger IRF7 dimerization. Several lines of evidence shown 
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here suggest that cFLIP is a bona fide inhibitor of IRF7 activation, and it disrupts IKKa-
IRF7 interactions as its antagonistic function.  
 
3.2 Materials and Methods  
 
Cell lines 
  The human embryonic kidney 293T, human cervical HeLa, and monocytic THP-1 
human cell lines were obtained from the American Type Culture Collection. The CAL-1 
plasmacytoid dendritic human cell line was kindly provided by Dr. Klinman (NCI, 
Maryland) and Dr. Maeda (Nagasaki University) (34). Cells were cultured in appropriate 
medium supplemented with 10% FBS (Thermo Fisher Scientific) and 1% penicillin 
streptomycin (Thermo Fisher Scientific).  
Plasmids and transfections 
  Plasmid pCI was obtained from Promega. Plasmids encoding a FLAG-tagged 
human cFLIPL (pcFLIPL) or cFLIPS (pcFLIPS) were published previously (13). Plasmid 
pCLD encodes a FLAG-tagged caspase-like domain of cFLIPL (residues 178-480) and 
was a gift from Dr. Condorelli (University of Naples, Naples, Italy). Plasmid pIRF3CA, 
which expresses a constitutively active IRF3, was a kind gift from Dr. Yoo (University of 
Illinois). A plasmid encoding a GFP-tagged IRF3 (pIRF3) was a kind gift from Dr. 
Michelle Arnold (LSU Health Sciences Center, Shrevport, LA). Plasmids IRF7 (pIRF7) 
and pIFNa were provided by Dr. Fanxiu Zhu (Florida State University, Tallahassee, FL). 
Plasmid pIRF7CA, which expresses a constitutively active IRF7, was a kind gift from 
was a kind gift from Dr. Luciana Castiello (Instituto Pasteur, Rome, Italy). A plasmid 
encoding a myc-tagged TRAF6 protein was used in this work. Plasmid pIKKa encodes a 
FLAG-tagged IKKa protein and was a kind gift from Dr. Ulrich Siebenlist (NIH, 
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Bethesda, MD). Plasmid pAIP encodes a myc-tagged AIP protein and was a kind gift 
from Dr. Harhaj (Johns Hopkins University, Baltimore, MD). Plasmid pRL-TK was 
purchased from Promega. Plasmid pifna6-luc was kindly provided by Dr. Sun (Shanghai 
Institutes for Biological Sciences, Shanghai Shi, China). Plasmids pil12p40-luc, pVpx 
(encoding a FLAG-myc-HA-tagged Vpx protein) and pIRF5 (encoding a GFP-tagged 
IRF5) were kindly provided Dr. Ratner (Washington University, St. Louis, USA). 
Plasmid DNA was transfected into cells using TransIT-2020 transfection reagent (Mirus 
Bio) following manufacturer’s protocol.  
Luciferase assays 
  Subconfluent 293T cellular monolayers were transfected with 50 ng pRL-TK, 450 
ng pil12p40-luc, and either 500 ng pIRF3CA, 500 ng of pIRF7 or 250 ng pIRF5 and 250 
ng pTRAF6 to quantify IRF5 transcriptional activation. In this case, cells additionally 
were co-transfected with 1000 ng pCI, pcFLIPL, or pVpx. To detect IRF7-specific 
induction of gene expression, 293T cells were transfected with 50 ng pRL-TK, 450 ng 
pinfa6-luc, and either 500 ng pIRF3CA, 500 ng of pIRF7 or 250 ng pIRF5 and 250 ng 
pTRAF6. In this case, cells additionally were co-transfected with 1000 ng pCI, pcFLIPL, 
or pAIP. Additionally, 293T cells were co-transfected with 50 ng pRL-TK, 450 ng 
pinfa6-luc, either 500 ng pCI or pIRF7CA, and 1000 ng pCI, pcFLIPL, or pAIP. To detect 
IRF7 activation in HeLa cells, subconfluent cellular monolayers were transfected with 50 
ng pRL-TK, 450 ng pinfa6-luc, 250 ng pIFNa, and 1000 ng pCI, pcFLIPL, or pAIP. At 
24 h post-transfection, HeLa cells were incubated in medium lacking or containing 3 µM 
CpG-A (ODN-2216, Invivogen) for 3 h. These same conditions were used to examine the 
effect of cFLIPS and CLD on IRF7 activation. In this case, HeLa cellular monolayers 
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were transfected with 50 ng pRL-TK, 450 ng pinfa6-luc, 250 ng pIFNa, and 1000 ng 
pCI, pcFLIPL, pcFLIPS or pCLD.  
All cells were harvested 24-27 h post-transfection, lysed, and luciferase activities 
were detected using the Dual Luciferase Reporter Assay System (Promega) and 
quantified using the Clarity Luminescence Microplate Reader (BioTek Instruments). 
Analysis of firefly and sea pansy luciferase activities was performed, as described 
previously (13). Values were normalized to those of untreated cells transfected with 
empty vectors. Values are shown as mean +/- SD. The Student’s t-test was used to 
determine statistical significance of inhibition of luciferase activity. A portion of each 
lysate was also analyzed for protein expression by immunoblotting.  
Co-immunoprecipitations  
  To examine potential IRF7-cFLIPL interactions, subconfluent 293T cells were co-
transfected with 500 ng pIRF7 or 500 ng pIRF3 and 1000 ng pcFLIPL or pAIP. For HeLa 
cells, subconfluent monolayers were co-transfected with 1000 ng pcFLIPL or pAIP. In 
experiments that examined IRF7-IKKa interactions, subconfluent 293T cells were co-
transfected with 500 ng pIRF7 and either 500 ng pIKKa or pTRAF6, and 1000 ng pCI or 
pcFLIPL. For co-immunoprecipitations of IKKa, 293T cells were transfected with 500 ng 
pIKKa and 1000 ng pCI, pcFLIPL or pIRF7. For CAL-1 cells, 108 control or cFLIPL-
expressing transduced cells were treated with 10 µM CpG-A for 3 h. In all cases, cells 
were lysed in Whole Cell Lysate lysis (WCL) buffer (Abcam) at 24 h post-transfection or 
post CpG-A treatment. Clarified supernatants were collected. A portion of each lysate 
was set aside for the purposes of detecting protein expression. The remaining sample was 
used for co-immunoprecipitations. Lysates were incubated with rabbit anti-IRF7 (Cell 
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Signaling), anti-IRF3 (Cell Signaling), anti-IKKa (Cell Signaling), or rabbit non-specific 
IgG (Cell Signaling) for 16 h at 4°C. Protein G-Sepharose beads (Invitrogen) in a 50% 
slurry were added to each sample and incubation with rotation for 6 h. Beads were 
collected and washed three times. Pelleted beads were suspended in Laemmli buffer 
containing 5% 2-ME and boiled for 5 min. Samples were analyzed for the presence of 
proteins by using immunoblotting. 
Immunoblotting  
  For all immunoblotting assays, the protein concentration of each lysate was 
determined by the 660 nm protein assay (Pierce). For phosphorylation assays, HeLa cells 
were seeded in 10 cm2 dishes and samples were lysed in 100 µl of lysis buffer to 
concentrate protein levels. An equal amount of protein from each lysate was 
electrophoretically separated by SDS-PAGE. Proteins were transferred to polyvinylidene 
difluoride membranes (Millipore). Antibody-antigen reactions were detected by using 
chemilluminescence reagents (Amersham and Thermo Scientific) and autoradiography. 
Primary antibodies include the following: monoclonal rabbit anti-IRF3 (Cell Signaling); 
monoclonal mouse anti-FLAG (Sigma-Aldrich); monoclonal rabbit anti-FLAG (Sigma-
Aldrich); monoclonal mouse b-actin (Calbiochem); monoclonal mouse anti-myc (Cell 
Signaling); monoclonal rabbit anti-myc (Cell Signaling); monoclonal rabbit anti-FLIP 
(Cell Signaling); monoclonal mouse anti-FLIP (7F10; Enzo); mouse anti-GFP (Sigma-
Aldrich); rabbit anti-IKKa (Cell Signaling); mouse anti-IKKa (Santa Cruz); rabbit anti-




Transduction of cells with lentiviruses  
  Lentiviruses containing either cFLIPL (lenti-FLIP) or no transgene (lenti-con) 
were produced by co-transfecting 293T cells with packaging plasmids pCMV-dR8.2 
(Addgene; 4.5 µg) and pCMV-VSV-G (Addgene; 1.8 µg), and either an empty vector 
(pTRIP-IRES-GFP-control; 6 µg) or a plasmid containing the cFLIPL gene (pTRIP- 
cFLIPL-IRES-GFP; 6 µg). At 48 h post-transfection, lentiviruses were isolated from 
cellular supernatants. Lentiviruses were concentrated with Lent-X Concentrator 
(ClonTech). THP-1 or CAL-1 cell lines were inoculated with lentiviruses by using 
spinfection. Briefly, 1 x 106 cells, 50  l concentrated virus and 10 µg polybrene in 1 ml 
of virus media (RPMI with 1% FBS) were centrifuged at 800 x g for 45 min at 37°C. 
After spinfection, media was aspirated and cells were resuspended in 1 ml fresh media 
(RPMI with 10% FBS) with 50 µl of concentrated virus and incubated at 37°C. At 24-72 
h post-infection, GFP expression was used as a visual marker of transduction. Cellular 
populations with at > 80% GFP expression were passaged for use as stably transduced 
cell lines (THP-1 cells) or used immediately for experimentation (CAL-1 cells). 
Trandsduced THP-1 cells were passaged no more than 4 times, checking for GFP 
expression after each passage.  
Reverse transcriptase quantitative-PCR (RT-qPCR)  
  THP-1 cells were incubated in medium absent or containing 10 ng/mL PMA for 
16 h to differentiate cells into macrophage-like cells. Differentiated THP-1 or CAL-1 cell 
lines were stably transduced with a control lentivirus (lenti-con) or lentivirus expressing 
cFLIPL (lenti-FLIP). Transduced cells were stimulated with 10 µM CpG-A for 5 h to 
stimulate the IRF7 signal transduction pathway (51). Total RNA was extracted from cells 
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using an RNAeasy extraction kit (Qiagen). cDNA was generating using the M-MuLV 
reverse transcriptase and poly dT oligonucleotides (New England BioLabs). Quantitative 
PCR was performed using a Mastercycler realplex EP (Eppendorf) and SoFast EvaGreen 
Super Mix (Bio-Rad) per manufacturer’s instructions. The following primers were used 
to PCR amplify cDNA: b-actin forward (5’-AGTTGCGTTACACCCTTTCT-3’), b-actin 
reverse (5’-ACCTTCACCGTTCCAGTTT-3’), ifna4 forward (5’-GATACTCCTGG 
CACAAATGG-3’), ifna4 reverse (5’-TCATGGAGGACAGAGATGG-3’), ifna6 forward 
(5’- CAGTTCCAGAAGGCTGAAG-3’), ifna6 reverse (5’- GAGTC 
CTTTGTGCTGAAGAG-3’). Changes in gene expression levels were calculated by the 
2DDCt method (31). For normalization, respective b-actin mRNA quantities for each 
cDNA sample were measured, and then each value was normalized to that of 
unstimulated control cells, whose value was set to one. For all samples, data are 
presented as the mean +/- SD from three independent experiments. The Student’s t-test 
was used to determine statistically significant differences in mRNA expression levels as 
compared to unstimulated cells.  
 
3.3  Results  
cFLIPL inhibits IRF7-induced luciferase activity independent of IRF3 and IRF5 
We previously published that cFLIPL inhibits IRF3-driven transcription by 
interrupting IRF3-CBP-DNA interactions (13). Due to the sequence and structural 
similarities of IRF3, IRF5, and IRF7 (14, 65), it was queried if cFLIPL could antagonize 
IRF5 or IRF7. 
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 Luciferase reporter assays have been developed to specifically detect IRF5 or 
IRF7 activation, which were used as a first step towards answering this question (7, 57). 
HEK293T (293T) cells were used because of their high transfection efficiency and their 
common use for luciferase reporter assays. In a previous study, we used the PRDIII 
promoter to detect IRF3 activation (13). Here, the il12p40 promoter was fused to a 
luciferase gene to assess IRF5 activation (61) (Figure 3.2A, 3.2B). Alternatively, the 
infa6 promoter was fused to a luciferase gene to assess IRF7 activation (58) (Figures 
3.2A, 3.2C, 3.2D). Figure 3.2B showed the specificity of the il12p40-luc plasmid for 
IRF5 activation; only cells transiently expressing IRF5 and TRAF6 stimulated luciferase 
gene expression robustly. Note that TRAF6 must be co-expressed with IRF5 for IRF5 
homodimerization and subsequent IRF5 activation. Over-expression of a constitutively 
active IRF3 (IRF3CA) or IRF7 did not stimulate luciferase gene expression significantly 
above levels of pCI-transfected cells, as expected. Under these conditions, cFLIPL had no 
effect on luciferase activity, suggesting that cFLIPL did not antagonize IRF5 activation. A 
control for this assay was cells expressing Vpx, an HIV protein that is known to inhibit 
IRF5 activation (7). 
Figure 3.2C showed the specificity of the infa6-luc plasmid for IRF7 activation; 
luciferase activity was robust only in cells over-expressing IRF7 proteins. Over-
expression of a constitutively active IRF3 (IRF3CA) or co-expression of IRF5 and 
TRAF6 did not stimulate luciferase gene expression significantly above levels of pCI-
transfected cells. Interestingly, cFLIPL inhibited IRF7-induced infa6-luc activity to a 
similar extent as AIP, a cellular protein known to inhibit IRF7 activation (66) (Figure 
3.2C).  
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Experiments in Figure 3.2C over-expressed IRF7 to stimulate IRF7 activation 
because 293T cells do not express sufficient levels of IRF7 to drive promoter activity 
(66). In contrast, HeLa cells express IRF7, and IRF7 protein levels are increased when 
cells are transfected with a plasmid encoding IFNa (33, 63). Using this approach, 
incubation of HeLa cells with CpG-A stimulates the TLR9-induced IRF7 signal 
transduction pathway (36). Using this system, CpG-A activated IRF7 in vector-
transfected cells, similar to another published report (Figure 3.2D) (36). cFLIPL 
significantly inhibited CpG-A-induced luciferase activity, and the extent of this inhibition 
was similar to the inhibition observed with AIP (Figure 3.2D). Thus, cFLIPL inhibited 
IRF7 activity in two separate experimental systems.  
cFLIPL does not associate with IRF7  
We published previously that cFLIPL binds to an IRF3-CBP complex to prevent 
enhanceosome formation (13). Since IRF3 and IRF7 are similar, one possibility was that 
cFLIPL would also interact with and inhibit IRF7. 
293T cells were initially used to test this hypothesis because these cells have high 
rates of transfection efficiency and are used routinely to detect protein-protein 
interactions (13). Epitope-tagged versions of IRF7 were expressed in 293T cells because 
293T cells have very low levels of endogenous IRF7 (48). As shown in Figure 3.3A, 
despite the abundance of IRF7 in these cells, a FLAG-tagged cFLIPL was not detectable 
in IRF7 immunoprecipitates. It was unlikely that this lack of detection was due to sub-
optimal conditions for protein-protein interactions because we detected IRF7 interacting 
with a known binding partner (AIP) (Figure 3.2A, left hand panel) (67). Also, we 
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detected cFLIPL interacting with IRF3, a known cFLIPL binding partner (Figure 3.3A, 
right hand panel) (13).  
A similar co-immunoprecipitation was performed in HeLa cells (Figure 3.3B). 
Endogenous IRF7 protein levels were detected in HeLa cells, allowing us to examine if 
cFLIPL interacted with endogenous IRF7. Similar to Figure 3.2A, cFLIPL was not 
detected in IRF7 immunoprecipitates. Again, IRF7-AIP interactions remained detectable, 
showing conditions were optimal for detecting IRF7 binding partners. Thus, it appeared 
that cFLIPL did not exert its antagonistic effects via interacting with IRF7.  
cFLIPL inhibits IRF7 phosphorylation 
One critical step in the TLR9-induced IRF7 activation pathway is IRF7 
phosphorylation at Ser 477 and Ser 479 (30). Once IRF7 is phosphorylated, IRF7 
changes conformation, exposing the interferon-association domain (IAD) to allow IRF7 
homodimerization, nuclear translocation, recruitment of critical co-factors, such as CBP 
(61), and DNA binding (35). 
Because cFLIPL did not co-immunoprecipitate with IRF7 (Figure 3.3), we asked if 
cFLIPL prevented IRF7 phosphorylation. To test this, HeLa cells were transfected with 
pIFNa to increase endogenous IRF7 expression, and then were stimulated with CpG-A, 
resulting in IRF7 phosphorylation (Figure 3.4A). Phospho-IRF7 was also observed when 
AIP was expressed in cells, and this was expected because AIP inhibits IRF7 activation 
downstream of IRF7 phosphorylation (67). In contrast, IRF7 phosphorylation was not 
detected in cFLIPL-expressing cells (Figure 3.4A). This suggested that cFLIPL targeted a 
signaling event upstream of IRF7 phosphorylation. Data in Figure 3.4B further supported 
this concept. In this luciferase reporter assay, a constitutively active IRF7 (IRF7CA) was 
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over-expressed. IRF7CA is sufficient to stimulate infa6-luc activity because 
phosphomimetic amino acid substitutions (Ser 477 and Ser 479 to Asp) yield an IRF7 
protein that is constitutively active (30, 39) cFLIPL did not inhibit the activity of a 
constitutively active IRF7 mutant suggesting it works upstream of phosphorylation. AIP 
blocked IRF7-controlled luciferase activity, and this was expected because AIP prevents 
nuclear translocation of IRF7 (67) (Figure 3.4B).  
The N-terminal DED-containing region of cFLIP is necessary to inhibit IRF7 
phosphorylation and activation 
Figure 3.5A shows that cFLIPL is comprised of two death effector domains 
(DEDs) and a C-terminus containing a caspase-like domain (CLD). In contrast, cFLIPS 
lacks the CLD. We published that the CLD of cFLIPL is sufficient to inhibit the IRF3 
activation pathway (13). Thus, the death effector domains (DEDs) were dispensable for 
cFLIPL’s inhibition of IRF3 activity. We were curious if the CLD also provided IRF7 
inhibition. We used the same IRF7-specific luciferase reporter assay as in Figure 3.2D to 
map the cFLIPL domain(s) required for inhibition. As shown in Figure 3.5B, cFLIPL and 
cFLIPS each significantly inhibited CpG-A induced ifna6-luc activity, suggesting that one 
or more DEDs possess the inhibitory function. These data also agree with Buskiewicz’s 
finding that cFLIPS inhibits IFNa production (4). However, the CLD did not antagonize 
IRF7 activation (Figure 3.5B). Consistent with luciferase assay results, cFLIPL and 
cFLIPS, but not the CLD, inhibited IRF7 phosphorylation (Figure 3.5C). Thus, the DED 




cFLIPL associates with IKKa and prevents IKKa-IRF7 interactions 
The data above showed that, while cFLIPL inhibited IRF7 phosphorylation, it did 
not bind to IRF7. Two kinases (IRAK1 and IKKa are reported to promote IRF7 
phosphorylation during TLR9 stimulation (21, 54). The current dogma is that the IRAK1- 
IKKa kinase cascade leads to phosphorylation of IRF7 (18, 21). Thus, we queried if 
cFLIPL may interact with IKKa to prevent IKKa from acting on its IRF7 target. To test 
the first possibility, co-immunoprecipitations were performed to examine interactions 
between IKKa and cFLIPL (Figure 3.6). For this experiment, epitope-tagged IKKa and 
cFLIPL were co-over-expressed in 293T cells. Figure 3.6A showed that cFLIPL indeed 
co-immunoprecipitated with IKKa. This was not unexpected given that a variant of 
cFLIPL (p43) was reported to bind to IKKa (37). As a control, we were also able to 
detect IKKa-IRF7 interactions in cells ectopically expressing IKKa and IRF7 (note that 
the thick band representing the heavy chain is a slightly different mobility than the IRF7-
containing band) (Figure 3.6A). Figure 3.6B then examined IRF7 co-
immunoprecipitations when IKKa, IRF7 and cFLIPL, and TRAF6 were ectopically 
expressed. We observed that IKKa-IRF7 interactions were greatly diminished when 
cFLIPL was present (Figure 3.6B), implying that cFLIPL competitively inhibited IRF7-
IKKa interactions. As expected, cFLIPL-IRF7 interactions were not detected, similar to 
observations seen in Figure 3.3. IRF7 activation by IKKa is preceded by its 
ubiquitination by TRAF6 (44, 54). Interestingly, over-expression of cFLIPL did not 
prevent IRF7-TRAF6 interactions (Figure 3.6B). This suggested that cFLIPL acted 
downstream of the formation of the MyD88-based complex containing TRAF6.        
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cFLIPL inhibits IRF7 in THP-1 and CAL-1 cell lines 
The above experiments showed that cFLIPL inhibited IRF7 activation in HeLa and 
293T cells. IRF7 is expressed at relatively high levels in hematopoietic cells like 
macrophages and pDCs (8, 28, 40, 49). If the cFLIP function identified in HeLa and 
293T cells was physiologically relevant, then cFLIPL should antagonize IRF7 activation 
in these professional APCs. To test this hypothesis, cFLIPL was stably introduced into the 
THP-1 human monocyte cell line via lentivirus transduction (60). We picked this cell line 
because PMA-treated THP-1 cells differentiate to macrophage-like cells (41). In this 
state, THP-1 cells respond to CpG-A stimulation and express high levels of IRF7-
controlled IFNa and ISG transcripts (6, 51). We also transduced the CAL-1 cell line with 
the same cFLIPL-expressing lentiviruses. The CAL-1 cell line originally was developed 
for use as a surrogate for primary plasmacytoid DCs (pDCs) to study type I IFN signaling 
and production (34). One benefit to using this cell line as opposed to primary human cells 
is that it avoids variation seen from donor to donor. While CAL-1 cells produce IFNa to 
a lesser extent than primary pDCs (34), the IRF7 signal transduction and activation 
pathway is maintained (34). As a control, a separate set of THP-1 and CAL-1 cells were 
transduced with lentiviruses that lacked the cFLIPL gene.  
Transduced THP-1 cells or CAL-1 cells were incubated with CpG-A to trigger 
IRF7 activation (28, 50, 53). The transcription of two genes known to be controlled by 
IRF7 homodimers - ifna4 and ifna6 – was examined to assess the function of cFLIPL 
inhibition in both cell lines (24). As shown in Figures 2.9A and 2.9B, CpG-A induced 
ifna4 and infa6 mRNA expression was significantly inhibited in cFLIPL-expressing THP-
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1 and CAL-1 cells, respectively, as compared to cells transduced with a virus lacking the 
cFLIPL gene.  
The cFLIPL molecular mechanism for inhibition of IRF7 activation appeared to be 
the same in CAL-1 cells as in HeLa and 293T cells. First, CpG-A-mediated IRF7 
phosphorylation was decreased in FLIP-expressing CAL-1 cells, and this correlated to 
decreased IKKa-IRF7 interactions (Figure 3.7C). In addition, IKKa-IRF7 complexes 
were only detected in CpG-A stimulated control cells, while the amount of IKKa-IRF7 
complexes were dramatically reduced in FLIP-expressing CAL-1 cells. It was also 
noticed that cFLIPL co-immunoprecipitated with IKKa in both unstimulated and 
stimulated cells. Thus, cFLIPL inhibits IRF7 activation by interacting with IKKa in 
physiologically relevant cells (Figure 3.7D). 
 
3.4 Discussion  
IRF7 is critical for IFNa gene expression (19, 20, 29). There is one previous 
report showing that cFLIP inhibits IFNa production (4). However, the antagonistic 
mechanism of cFLIP remained unknown. The goal here was to identify this function by 
examining the effect of cFLIPL on well-known signal transduction events of the TLR9-
induced IRF7 activation pathway. We observed that cFLIPL prevented IRF7 
phosphorylation. IKKa is one well-known IRF7 kinase (21). We performed co-
immunoprecipitation assays and found that IRF7- IKKa interactions were abrogated by 
cFLIPL, concomitant with cFLIPL- IKKa interactions. Thus, we conclude that cFLIPL 
disrupts IRF7-IKKa interactions, interactions that are otherwise required for IRF7 
activation.  
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To the best of our knowledge, this is the first report of a cellular protein that 
disrupts IKKa-IRF7 interactions as a strategy to antagonize IRF7 activation. Most 
cellular IRF7 antagonists target IRF7 itself. For example, AIP binds to IRF7, and this 
interaction prevents IRF7 nuclear translocation (67). RAUL inhibits IRF7 (and IRF3) by 
targeting these IRFs for proteosomal degradation (64). Other proteins act indirectly on 
IRF7. Namely, TGF-b1 promotes K63-linked ubiquitination of TRAF6, which correlated 
with a decrease in IRF7 phosphorylation through unknown mechanisms (36). The myriad 
cellular strategies to decrease IRF7 activation is a testament to how the host cell has 
evolved multiple mechanisms to achieve immune system homeostasis. 
Within the family of IRF proteins, IRF3 and IRF7 are most closely related (65). 
There are several lines of evidence showing that cFLIPL antagonizes IRF7 using a 
mechanism distinct from its strategy to antagonize IRF3. For example, cFLIPL inhibited 
CpG-A-induced IRF7 activation, a signaling pathway that does not activate IRF3 (19, 26, 
42). Second, the domain of cFLIPL required for IRF7 activation (tandem DEDs) is 
distinct from the region required for IRF3 inhibition (CLD) (13). Third, cFLIPL co-
immunoprecipitates with IRF3 but not IRF7 (13). Thus, cFLIPL has at least two separate 
mechanisms to antagonize type I IFN production in cells. These functions of cFLIPL may 
be useful considering that there is differential expression of IFNa and IFNb by different 
cell types. For example, while IFNb is produced largely by fibroblasts (45), the major 
expressers of IFNa are pDCs (23). Indeed, cFLIP is expressed in these cells, suggesting 
cFLIP has evolved to control type I IFN production across various cell types (55). 
However, it appears that cFLIPL is not a pan-IRF inhibitor; cFLIPL did not inhibit IRF5-
controlled il12p40-based luciferase activity in our hands.  
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There is one previous report that shows that cFLIPS inhibits type IFNa and IFNb 
production (4). Buskiewicz et al. proposed that cFLIP modulates the MAVS complex to 
inhibit IFNb production, but the mechanism for inhibition of IFNa expression was not 
elucidated (4). We show here that both cFLIPS and cFLIPL inhibit IR7 activation, and 
IFNa production. It is possible that this mechanism was responsible for the inhibition of 
IFNa production that was observed by Buskiewicz et al.  
There remains some controversy with respect to the roles of IRAK1 and IKKa as 
IRF7 kinases. Of course, each protein is critical for IFNa production (21, 54). However, 
it remains unknown if (i) IRAK1 phosphorylates IKKa  which then goes on to 
phosphorylate and activate IRF7, or (ii) IRAK1 and IKKa each phosphorylate IRF7 at 
different residues to activate IRF7 (18). In our hands, cFLIPL significantly reduces IRF7 
phosphorylation while still allowing TRAF6-IRF7 interactions. Since TRAF6-IRF7 
interactions occur downstream of IRAK1 kinase activity (44, 54), IRAK1 signaling 
events are probably not compromised in the presence of cFLIPL. Thus, we currently 
suspect that cFLIPL targets IKKa but not IRAK1. 
We show here that cFLIPL co-immunoprecipitates with IKKa resulting in a block 
in IRF7 activation. Neumann et al. report that the p43 form of cFLIPL binds to IKKa, and 
this interaction activates the NF-kB pathway (37). It is unlikely that cFLIP-induced NF-
kB activation indirectly contributed to IRF7 inhibition because NF-kB activation 
stimulates IRF7 expression during TNF stimulation (5). Nevertheless, it is quite 
interesting that cFLIPL and p43 appear to have diametrically opposed functions: cFLIPL 
inhibits IRF3 and IRF7, while p43 activates NF-kB (3, 13, 37). Thus, cFLIP may down-
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regulate type I IFN responses while still allowing expression of other cytokine or 
chemokine genes controlled by NF-kB. How this may balance an appropriate immune 
response remains a mystery. 
Several groups target silencing of the cFLIP gene (cflar) to activate apoptosis in 
tumor cells (11, 46, 59). However, our data raise the possibility that over-expression of 
cFLIP may prove useful as a treatment for some types of autoimmune diseases to down-
regulate IFNa production (10, 16). Thus, cFLIPL may be one protein that could be 



















Figure 3.1 Proposed mechanism for cFLIP-mediated inhibition of IRF7-driven 
IFNa production. Activation of endosomal TLRs such as TLR7 by ssRNAs and TLR9 
by CpG motifs (e.g. CpG-A) leads to recruitment of the MyD88 protein. Next is the 
formation of a dynamic complex including at least IRAK4, IRAK1 and TRAF6. This 
complex triggers TRAF6-mediated K63-linked ubiquitination of IRF7, followed by IRF7 
phosphorylation. A current favored model proposes that IRAK4 phosphorylates IRAK1, 
leading to phosphorylation of IKKa. IKKa in turn activates IRF7. Phosphorylated IRF7 
homodimerizes and translocates to the nucleus, where it drives expression of IFNa. Data 
shown here suggest that cFLIP binds to IKKa in a manner that prevents IKKa-mediated 




Figure 3.2 cFLIPL inhibits IRF7-induced gene expression independent of IRF3 and 
IRF5. (A) A schematic representation of strategies used to study IRF5 or IRF7 activation 
independent of IRF3 activation using luciferase reporter assays. Over-expression of IRF5 
and TRAF6 specifically activate IRF5-controlled il12p40-luc expression. Over-
expression of IRF7 in 293T cells or stimulation of HeLa cells with CpG-A activates the 
IRF7-controlled ifna6-luc reporter. (B and C) 293T cells were co-transfected with (B) 
450 ng pil12p40-luc or (C) 450 ng pifna6-luc and 50 ng pRL-TK, 1000 ng pCI, 
pIRF3CA, or pIRF7or 500 ng each of pIRF5 and pTRAF6. Cells were also co-transfected 
with either 1000 ng pCI, pcFLIPL, or (B) pVpx or (C) pAIP. Cells were incubated for 24 
h post-transfection. (D) HeLa cells were co-transfected for with 450 ng pifna6-luc, 50 ng 
pRL-TK, 250 ng of pIFNa, and 1000 ng pCI, pcFLIPL, or pAIP. At 24 h post-
transfection, cells were incubated in medium lacking or containing 3 µM CpG-A for 3 h. 
For all experiments, cellular lysates were examined for luciferase activities. Results are 
shown as fold-induction of luciferase activity, relative to those of pCI-transfected cells. A 
portion of each lysate additionally was examined for protein expression by using 
immunoblotting to detect FLAG-tagged cFLIPL, myc-tagged Vpx, or myc-tagged AIP. 
Data are expressed as the mean +/- SD. Statistically significant differences in 




Figure 3.3 cFLIPL does not co-immunoprecipitate with IRF7. (A) 293T cells were co-
transfected with 500 ng pIRF7 or pIRF3 and 1000 ng pCI, pcFLIPL, or pAIP. At 24 h 
post-transfection, cells were lysed. A portion of each lysate was incubated with anti-
IRF7, anti-IRF3 antibodies, or non-specific IgG. Immunoblot (IB) analysis of 
immunoprecipitated (IP) samples was performed to detect FLAG-tagged cFLIPL, myc-
tagged AIP, IRF7 or IRF3. (B) HeLa cells were transfected with 1000 ng pcFLIPL or 
pAIP. At 24 h post-transfection, cells were lysed, and portion of each lysate was 
incubated with anti-IRF7 or non-specific IgG antibodies. Immunoblot (IB) analysis of IP 
samples was performed to detect FLAG-tagged cFLIPL, myc-tagged AIP and IRF7. For 
all IPs, a portion of each whole cell lysate (WCL) was also examined by immunoblotting 
to confirm expression of the proteins of interest. 
112	  	  
 
Figure 3.4 cFLIPL inhibits IRF7 phosphorylation. (A) HeLa cells were transfected 
with 1.5 µg pIFNa and 6 µg pCI, pcFLIPL, or pAIP. At 24 h post-transfection, cells were 
incubated with medium lacking or containing 3 µM CpG-A for 3 h. Cells were lysed and 
immunoblotting was performed to detect phospho-IRF7, IRF7, FLAG-tagged cFLIPL, 
myc-tagged AIP, and b-actin proteins. (B) 293T cells were co-transfected with 450 ng 
pifna6-luc, 50 ng pRL-TK, 1000 ng pCI, cFLIPL, or pAIP and 500 ng pCI or pIRF7CA. 
At 24 post-transfection, cells were lysed and luciferase activities were quantified. Results 
are shown as fold-induction of luciferase activity relative to those of unstimulated, pCI-
transfected cells. Immunoblot analysis of whole cell lysates also was performed to detect 
FLAG-tagged cFLIPL and myc-tagged AIP. Experiments shown here are representative 
of experiments performed at least three times. Data are expressed as the mean +/- SD. 
Statistically significant differences in experimental samples when compared to cells 
transfected with empty vector are denoted with an * (p<0.05). 
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Figure 3.5 The N-terminal DEDs of cFLIP inhibit IRF7 activation. (A) Schematic 
representation of the wild-type and mutant (CLD) cFLIPL protein and the alternative 
splice variant cFLIPS. cFLIPL and cFLIPS each contain tandem death effector domains 
(DEDs) while only cFLIPL possesses a caspase-like domain (CLD). (B) HeLa cells were 
co-transfected with 450 ng pifna6-luc, 50 ng pRL-TK, 250 ng pIFNa, and 1000 ng of 
pCI, pcFLIPL, pcFLIPS, or pCLD. At 24 h post-transfection, cells were incubated in 
medium lacking or containing 3 µM CpG-A for 3 h. Cells were lysed, and luciferase 
activities were quantified. Results are shown as fold-induction of luciferase activity, 
relative to those of untreated pCI-transfected cells. Immunoblot analysis of lysates also 
was performed. Data are expressed as the mean +/- SD. Statistically significant 
differences in experimental samples when compared to cells transfected with empty 
vector are denoted with an * (p<0.05). (C) HeLa cells transfected with 1.5 µg pIFNa and 
6 mg pCI, pcFLIPL, pcFLIPS, or pCLD . At 24 h post-transfection, cells were incubated 
with medium lacking or containing 3 µM CpG-A for 3 h. Cells were lysed in 100 µl to 
concentrate proteins and immunoblotting was performed to detect phospho-IRF7, total 
IRF7, each FLAG-tagged FLIP, or b-actin. 
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Figure 3.6 cFLIPL associates with IKKa and prevents IKKa-IRF7 interactions. (A) 
293T cells were co-transfected with 1000 ng pIKKa, pCI, pcFLIPL, and pIRF7 as 
indicated. At 24 h post-transfection, cells were lysed and a portion of each lysate was 
incubated with anti-IKKa or non-specific IgG antibodies. Immunoblot (IB) analysis of IP 
samples was performed to detect FLAG-tagged cFLIPL, IKKa, or IRF7. (B) 293T cells 
were co-transfected with 500 ng pIRF7, 1000 ng pCI or pcFLIPL, 500 ng pIKKa and 500 
ng pTRAF6 as indicated. At 24 h post-transfection, cells were lysed and a portion of each 
lysate was immunoprecipitated (IP) with anti-IRF7 or non-specific IgG antibodies. A 
separate portion of each lysate was used to examine protein expression levels. 
Immunoblot (IB) analysis of co-IP’ed samples was performed to detect IKKa, myc-
tagged TRAF6, FLAG-tagged cFLIPL, or IRF7 proteins. For all lysates, immunoblot 
analysis of whole cell lysates also was performed. *H.C. denotes heavy chain.  
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Figure 3.7 cFLIPL inhibits IRF7 activation and IKKa-IRF7 interactions in THP-1 
and CAL-1 cell lines. (A) THP-1 cells and (B) CAL-1 pDC cells were transduced with a 
control lentivirus (con), or cFLIPL -expressing lentivirus (FLIP). THP-1 cells were 
differentiated into macrophages by treatment with PMA (10 ng/ml for 16 h). Transduced 
cells were incubated with media lacking or containing 10 µM CpG-A for 5 h. Cells were 
lysed and total RNA was extracted. A portion of each lysate was also used to detect 
cFLIPL protein expression. The level of ifna4 and ifna6 mRNA was quantified by using 
RT-qPCR. (C) Transduced CAL-1 cells were incubated in medium lacking or containing 
10 µM CpG-A for 5 h. Cells were then lysed and a portion of lysate was 
immunoprecipitated with anti-IRF7 or non-specific IgG antibodies. Immunoblot (IB) 
analysis of IP samples was performed to detect endogenous p-IRF7, IKKa, cFLIPL, or 
IRF7. A portion of each lysate prior to immunoprecipitation was also analyzed for protein 
expression (note that p-IRF7 could not be detected without co-immunoprecipitation). (D) 
Transduced CAL-1 cells were incubated in medium lacking or containing 10 µM CpG-A 
for 5 h. Cells were then lysed and a portion of lysate was immunoprecipitated with anti-
IKKa or non-specific IgG antibodies. Immunoblot (IB) analysis of IP samples was 
performed to detect endogenous IKKa, cFLIPL, or IRF7. A portion of each lysate prior to 
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Chapter 4: Cytokine expression in a cerulein-induced model of acute pancreatitis 
These data were presented at the Proceedings of the 2017 IEEE Ultrasonics Symposium 
as part of the research project: “Quantitative Ultrasound and the Pancreas: Demonstration 
of Early Detection Capability” conducted by Rita Miller et al.  
 
4.1 Introduction  
Pancreatitis is inflammation of the pancreas, which can present as an acute 
condition (sudden onset) or a chronic condition (occurring over many years).  Acute 
pancreatitis is a common disease in which most patients recover without treatment; 
however, a significant number of patients (~ 20%) progress to severe clinical disease that 
can be life threatening (3). Research advances are needed to develop a quick, relatively 
easy and inexpensive diagnostic technique that will diagnose early onset pancreatitis in 
order to increase survival rate, optimize treatments to improve outcomes, and potentially 
reverse detrimental disease effects. Transcription of pro-inflammatory genes was the 
method I exploited to help Miller et al. investigate this. She hoped to use these data along 
with quantitative ultrasound (QUS), and histopathology to advance our understanding of 
developing rapid diagnostic techniques for acute pancreatitis. Here, Miller et al. used a 
cerulein-induced rat model of acute pancreatitis and monitored the course of the disease 
over a 168 hr (1 week) time period (9). I measured gene transcription of selected 
cytokines and chemokines that are markers of severity of acute inflammation, IL-6 and 
the IL-8-like protein in rats, CINC-1. 
Interleukin 6 (IL-6) is a pro-inflammatory cytokine that is produced by immune 
cells: histiocytes, T cells, macrophages, and fibroblasts (2). It is expressed in response to 
viral or bacterial infections as well as trauma, such as burns. IL-6 is a critical mediator for 
the acute phase response and is upregulated during acute pancreatitis (7). There is 
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substantial evidence that IL-6 contributes to pancreatic cancer development and 
progression (2). Here, we asked when we could detect il6 expression during a cerulein-
induced model of acute pancreatitis is rats, and if this could be a method for also 
investigating pancreatic cancer progression in pancreatic cancer models in rats.  
Interleukin 8 (IL-8), also known as neutrophil chemotactic factor, is a chemokine 
produced by macrophages and it is important for stimulating chemotaxis of neutrophils. 
IL-8 is not produced in rats, but a homolog, cytokine induced neutrophil chemoattractant 
(CINC-1), serves an almost identical purpose (8). CINC-1 levels increase during acute 
pancreatitis, and in 2000, Bhatia demonstrated that antibodies against CINC-1 protected 
rats against acute pancreatitis during cerulein-induced acute pancreatitis (1). These data 
suggest that cinc1 expression is critical for pathogenesis of acute pancreatitis, so we 
investigated its expression over time in the cerulein model of pancreatic disease.  
Using IL-6 and CINC-1 as markers for acute pancreatitis, we found that il6 
expression was highest 24 hr after rats were injected with cerulein. Alternatively, cinc1 
levels began to rise as early as 2 hr, increased to peak levels by 4 hr and maintained high 
expression until 60 hr post-injection. Based on these data, one may use cinc1 expression 
as a better marker for acute pancreatitis, due to its long lasting production, compared to 
il6 expression. Still, observing il6 expression in patients with acute pancreatitis will give 






4.2 Materials and Methods 
Animal protocol  
Eighty-one female Sprague-Dawley rats were purchased from Envigo 
(Indianapolis, IN). At time of injection they were 12.5-16.0 wks of age with an average 
body weight of 228 g. The rats were divided into 10 scanning groups; cage control (no 
cerulein or saline injected), saline control (saline injected), and 2 hr, 4 hr, 15 hr, 24 hr, 48 
hr, 60 hr, 72 hr, and 168 hr post-cerulein injection. For the paper, I successfully measured 
cytokine mRNA expression for the cage control, saline control, and 2 hr, 4 hr, 24 hr, and 
60 hr post-cerulein injection groups, after optimizing the preparation protocol. Before 
optimization (dating before April of 2017), I measured cytokine mRNA expression for 
cage control, 4 hr, 15 hr, 24 hr, 48 hr, 72 hr, and 168 hr post-cerulein injection groups. 
Except for the two control groups, each unanesthetized rat received 40 µg/kg (100 µL) of 
sulfated cerulein injected intraperitoneally (IP) hourly four times (9). The cage controls 
received no injections; the saline control group received 100 µL of sterile saline injected 
IP hourly four times and were euthanized 2 hrs after the last saline injection. No evidence 
of abdominal pain or any other clinical signs from the cerulein injections were seen over 
the course of this study. Immediately following in vivo ultrasonic imaging, rats were 
euthanized while still under anesthesia. Immediately after euthanasia, the pancreas was 
removed en masse and weighed. A piece of pancreatic tissue no thicker than 2 mm was 
removed from the splenic region for ex vivo ultrasonic scanning. Before optimizations 
(dating before 2017), the remaining tissue was weighed, flash frozen in liquid nitrogen, 
and then stored at - 80ºC in 5 ml conical tubes for further biochemical analysis (gene 
transcription). After optimization, the remaining tissue was weighed, flash frozen in 
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liquid nitrogen, and then stored at - 80ºC 1.5 ml Eppendorf tubes containing a 7 mm 
stainless steel bead for further biochemical analysis (gene transcription). The 
experimental animal protocol was approved by the Institutional Animal Care and Use 
Committee of the University of Illinois at Urbana-Champaign and satisfied all campus 
and National Institutes of Health rules for the humane use of laboratory animals. Animals 
were housed in an Association for Assessment and Accreditation of Laboratory Animal 
Care approved animal facility and provided food and water ad libitum.  
Gene transcription (before optimization) 
Pancreases from rats untreated, or injected with cerulein were removed 0, 4, 15, 
24, 48, 72, and 168 h post-treatment. They were flash frozen in liquid nitrogen and stored 
in -80 degrees in 5 ml conical tubes until further use. For each frozen pancreas, a small 
section was removed and RNA was extracted. Each sample was placed into a tube 
containing a 7 mm stainless steel bead. RNA was extracted using the RNeasy kit. Briefly, 
pancreases were placed into pre-frozen tubes for 15 minutes to minimize RNA 
degradation. Next, tissues were placed in the tissue lyser at 50 Hz for 3 minutes at room 
temperature. Tubes were then mixed by inverting, and subjected to another round of 
homogenization. Homogenates from each pancreas half were combined into one tube and 
centrifuged at 18,000 x g for 3 min. Supernatants were transferred to new tubes and one 
volume of 70% ethanol was added. Total RNA was isolated following the manufacturer’s 
directions. RNA was quantified and two µg of RNA from each pancreas sample was 
reverse transcribed to cDNA as follows.  Briefly, total RNA was incubated with 0.5 µg of 
oligo dT primer (IDT) and (M-MulV) Reverse Transcriptase (New England BioLabs) at 
70° C for 5 minutes, followed by a 5 minute incubation at 4° C, as per manufacturer’s 
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instructions. Quantitative PCR was performed using a Mastercycler realplex EP 
(Eppendorf) and SoFast EvaGreen Super Mix (Bio-Rad) per manufacturer’s instructions. 
The following primers were used: rat b-actin forward (5’-CAACTG 
GGACGATATGGAGAA-3’) and reverse (5’-CTCGAAGTCTAGGGCAACATA-3’), 
rat il6 forward (5’-CAGGAACGAAAGTCAACTCC-3’) and reverse (5’-CAACA 
TCAGTCCCAAGAAGG-3’), and rat cinc1 forward (5’-CGAAGTCATA  
GCCACACTCAA-3’) and reverse (5’-CTCACACATTCCTCACCCTAAC-3’). Changes 
in gene expression level were calculated by the 2DDCT method. Values obtained from il6, 
and cinc1 cDNA levels were divided by b-actin levels for each sample. For 
normalization, respective b-actin mRNA quantities for each cDNA sample were 
measured, and then each value was normalized to that of the saline control rats, whose 
value was set to one.  
Gene transcription (after optimization) 
Pancreases from rats untreated, injected with saline, or injected with cerulein were 
removed 0 hr, 2 hr, 4 hr, 24 hr, or 60 hr post-treatment. For each pancreas, a small section 
was removed, flash frozen in liquid nitrogen, and placed into 1.5 ml Eppendorf tubes 
containing a 7 mm stainless steel bead. They were stored in -80 degrees until further use. 
RNA was extracted using the RNeasy kit. Briefly, pancreases in frozen tubes were placed 
in the tissue lyser at 50 Hz for 3 minutes at room temperature. Tubes were then mixed by 
inverting, and subjected to another round of homogenization. Homogenates from each 
pancreas half were combined into one tube and centrifuged at 18,000 x g for 3 min. 
Supernatants were transferred to new tubes and one volume of 70% ethanol was added. 
Total RNA was isolated following the manufacturer’s directions. RNA was quantified 
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and two µg of RNA from each pancreas sample was reverse transcribed to cDNA as 
follows.  Briefly, total RNA was incubated with 0.5 µg of oligo dT primer (IDT) and (M-
MulV) Reverse Transcriptase (New England BioLabs) at 70° C for 5 minutes, followed 
by a 5 minute incubation at 4° C, as per manufacturer’s instructions. Quantitative PCR 
was performed using a Mastercycler realplex EP (Eppendorf) and SoFast EvaGreen 
Super Mix (Bio-Rad) per manufacturer’s instructions. The following primers were used: 
rat b-actin forward and reverse, rat il6 forward and reverse, and rat cinc1 forward and 
reverse. Changes in gene expression level were calculated by the 2DDCT method. Values 
obtained from il6, and cinc1 cDNA levels were divided by b-actin levels for each sample. 
For normalization, respective b-actin mRNA quantities for each cDNA sample were 
measured, and then each value was normalized to that of the saline control rats, whose 
value was set to one.  
 
4.3 Results  
Maintaining the integrity of rat pancreas samples is critical for quality RNA extraction 
for qPCR analysis 
Before RNA extraction optimizations, I evaluated gene transcription at selected 
time points of 3 cytokine markers, ifnb1, and 2 markers for acute inflammation that are 
expressed routinely in acute pancreatitis (6), il6 and cinc1 (rat IL-8-like protein) (Figure 
4.1). Expression of all three genes declined below cage control expression at 4, 15, 24 
and 48 h, which was not expected. Further, expression of all three genes started to 
increase above cage control expression at 72 and 168 h, but this expression was not 
striking (only 3.5 x cage control). Error bars for all samples were very large (Figure 4.1). 
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These data suggested to me that the quality of RNA used was poor, most likely because 
the samples began thawing during transfer of sample from 5 ml conical tubes to the 1.5 
ml Eppendorf tubes.  
Expression of il6 and cinc1 overtime during cerulein-induced pancreatitis 
After optimizing the RNA extraction protocol by keeping pancreas tissue frozen 
until RNA extraction, I evaluated gene transcription at selected time points of 2 markers 
for acute inflammation that are expressed routinely in acute pancreatitis (6), il6 and cinc1 
(rat IL-8-like protein) (Figure 4.2). Expression of il6 stayed low over time until peaking 
at 24 hr post-cerulein treatment. The levels of il6 decreased again by 60 hr. Expression of 
cinc1 began much earlier than il6 expression, starting at 2 hr and rising until 4 hr, where 
it maintained high levels of expression until 60 hr post-cerulein treatment (Figure 4.2). 
The expression of these cytokines correlates to histological data collected during this 
project (data not shown) such that the histiocytes (IL-6 producers) accumulated to peak 
numbers by 24 h post-cerulein injection. Further, neutrophils (CINC-1 producers) 
accumulated early on (4 h post-cerulein injection) and maintained their numbers 
throughout the study (data not shown). These data suggest that il6 and cinc1 are 









Understanding the progression of acute pancreatitis (as with pancreatic cancer) is 
imperative for successful intervention and treatment. This cerulein-induced model of 
acute pancreatitis in rats lends itself well to the study of early pancreatitis detection as the 
degree of pancreatitis is mild, all animals survive and the induction of pancreatitis 
resolves in ~7 days, allowing for assessment of earlier, reversible changes. IL-6 mRNA 
expression increased substantially over time in accordance with the observed 
accumulation of histiocytes (major IL-6 producers), which take substantially longer to 
accumulate than neutrophils (major CINC-1 producers). CINC-1 mRNA expression 
increased as neutrophils accumulated in the pancreatic interstitium, peaking at 4 hr and 
maintaining its expression at least 60 hr post-injection.  
Miller et al. used these data along with ultrasound techniques and histology to ask 
how early they could detect acute pancreatitis in hopes of increasing the prognosis of 
patients afflicted with this condition (5). Ultrasonically they saw measurable effects on 
two quantitative ultrasound (QUS) techniques, attenuation coefficient (AC) and 
backscatter coeffiecient (BSC) of cerulein-injected rats compared to controls that reflect 
the effects over time of cerulein, suggesting that QUS will be sensitive enough to detect 
early changes in the pancreas. AC is a quantitative measure of ultrasonic energy loss with 
distance and BSC is a quantitative measure of echogenicity (4).  The general trend is 
decreased AC and BSC at early time points and then increases relative to controls (cage 
and saline) at later time points. Briefly, this describes the QUS through the healthy 
pancreas, versus a pancreas injected with cerulein to mimic acute pancreatitis. At 2 hr 
post cerulein the AC and BSC effects are significant suggesting QUS detection limits less 
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than 2 hr, which is how early cinc1 expression could also be detected. These results 

























Figure 4.1 Relative fold change in mRNA expression vs. hours following last 
cerulein injection for ifnb1, il6, and cinc1 before optimizations. Rats were either left 
untreated (cage control) or injected with cerulein and sacrificed at 4, 15, 24, 48, 72, or 
168 hr post-injection. Pancreases were removed, flash frozen in liquid nitrogen and 
placed in 5 ml conicals. Before RNA extraction, a small portion of each pancreas was 
thawed and sectioned and placed in 1.5 ml Eppendorf tubes containing a 7 mm stainless 
steel bead. RNA was extracted and the level of ifnb1, il6, and cinc1 mRNA was 















Figure 4.2 Relative fold change in mRNA expression vs. hours following last 
cerulein injection for il6, and cinc1 after optimizations. Rats were either injected with 
saline, (saline control), left untreated (cage control) or injected with cerulein and 
sacrificed at 2, 4, 24, or 60 hr post-injection. Pancreases were removed, flash frozen in 
liquid nitrogen and placed 1.5 ml Eppendorf tubes containing a 7 mm stainless steel bead. 
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Chapter 5: Summary of thesis and future directions 
 
5.1 Summary 
  The cellular FLICE-like inhibitory protein (cFLIP) is a potent inhibitor of type 
IIFNs, both IFNb and IFNa. Previous studies showed that cFLIPL could inhibit IFNb 
luciferase activity and transcription (3, 8). Further, cFLIPS was identified as an inhibitor 
of IFNa production (2). My work elucidated the mechanism of cFLIP-mediated 
inhibition of the IRF3 and IRF7 transcription factors, which are critical for the production 
of IFNb and IFNa respectively (Gates and Shisler, 2016; Gates and Shisler, submitted 
2017).  
Prior to my work, viral FLIPs had been investigated for their mechanism of 
inhibition of IFNb. One such example was the MCV MC159 protein, which inhibits 
IFNb production by binding to the kinase complex of TBK1-IKKe, and preventing its 
phosphorylation as well as the phosphorylation of IRF3 (8). Because cFLIP is a structural 
homolog of viral FLIPs like MC159, I hypothesized that cFLIP may inhibit IFNb 
production by a similar mechanism. Interestingly, this was not the case. I found that 
cFLIPL, specifically, the caspase-like domain (CLD) of cFLIPL, but not cFLIPS, inhibited 
IFNb production by disrupting IRF3-CBP-DNA interactions (Chapter 2). These data 
appeared to be physiologically relevant, because when cflar expression was dampened in 
three tumor cell lines known to overexpress cFLIP (9), IRF3-driven transcription was 
significantly increased, suggesting that some tumors exploit cFLIP over-expression to 
dampen type I IFN production in the tumor microenvironment (Figure 2.9).  
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  Since IRF3 and IRF7 are the most structurally similar IRFs (4, 12), and there was 
prior evidence that cFLIP could inhibit IFNa production (2), which is largely driven by 
IRF7 (5), I wanted to investigate the mechanism of cFLIP-mediated inhibition of IRF7-
driven IFNa expression.  Interestingly, cFLIP did not co-IP with IRF7 (Figure 3.3), 
which was unexpected since it does co-IP with IRF3, and this is imperative for its IRF3 
inhibitory function. Alternatively, cFLIPL co-IP’d with the IRF7 kinase, IKKa (Figure 
3.6). By interacting with IKKa, IRF7 phosphorylation was inhibited, and downstream 
IRF7-mediated signaling was abolished (Chapter 3). This mechanism appeared to be 
physiologically relevant because we tested it within a pDC cell line, CAL-1 cells, that 
were transduced with a lentivirus over-expressing cflar (Figure 3.7). Plasmacytoid 
dendritic cells (pDCs) are the major producers of IFNa within humans, and its 
overproduction of IFNa is what contributes to the pathogenesis of lupus (1). This newly 
identified role of cFLIP could potentially be exploited for therapeutic purposes against 
autoimmune disorders linked to up-regulation of IFNa. 
  During my PhD studies, I became well versed in performing RT-qPCR. Miller et 
al. was focusing on early detection of acute pancreatitis with quantitative ultrasound 
(QUS) techniques and inquired whether I could perform RT-qPCR on markers of acute 
pancreatitis that could supplement their QUS and histological data. After thorough 
literature search, I concluded IL-6 and IL-8 expression were informative biomarkers for 
acute pancreatitis (7). Miller et al. utilized a model of acute pancreatitis in rats injected 
with cerulein (5, 11). Rats do not express IL-8, but they do express a homolog, CINC-1 
(10). I measured il6 and cinc1 levels during a time course spanning 0 and 60 hr post-
cerulein injection. I found that il6 expression increased substantially over time (Figure 
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4.2) in accordance with the observed accumulation of histiocytes (major IL-6 producers), 
which take substantially longer to accumulate than neutrophils (major CINC-1 producers) 
(data not shown). Further, cinc1 mRNA expression increased as neutrophils accumulated 
in the pancreatic interstitium (data not shown), peaking at 4 hr and maintaining its 
expression at least 60 hr post-injection (Figure 4.2) (Chapter 4). In summary, when using 
IL-6 and CINC-1 as markers for acute pancreatitis in this specific model, one should 
consider the striking upregulation of il6 at 24 h compared to the steady expression of 
cinc1 over the course of 4-60 h. Expression of both genes gives temporal specificity (il6) 
and indication of acute pancreatitis (cinc1) which may lend itself to the early detection of 
this potentially detrimental condition.  
 
5.2  Future Directions 
cFLIPL inhibition of IRF3  
  My work demonstrated that the CLD of cFLIPL co-IP’ed with IRF3 and this 
correlated to a loss of IRF3-CBP and IRF3-DNA interactions (Chapter 2). The CLD 
contains a nuclear localization signal (NLS) which prompted the question of whether or 
not cFLIPL is “waiting” in the nucleus before interacting with nuclearly localized IRF3, 
or if it interacts with IRF3 within the cytoplasm “catching a ride” with IRF3 into the 
nucleus. One could attempt to answer this question by utilizing cellular fractionation and 
co-immunoprecipitation techniques to investigate IRF3-cFLIPL interactions in the 
cytoplasm or the nucleus, with or without stimulation of the IRF3 pathway. In addition, 
while the region of cFLIPL that interacts with IRF3 has been identified (Chapter 2), the 
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region of IRF3 involved in IRF3-cFLIPL interactions has not yet been identified. 
Truncation mutants of IRF3 could be used to answer this question.  
cFLIP-mediated inhibition of IRF7 and IFNa in diseased PBMCs  
As a result of my thesis work, it is clear that cFLIP is a potent inhibitor of IRF7-
mediated IFNa expression (Chapter 3). From a clinical standpoint, I was very interested 
in investigating cFLIP as an inhibitor of IFNa expression in the context of lupus. To test 
this, I planned to transduce healthy and (SLE) diseased PBMCs (SLE-PBMCs) (acquired 
from Stemcell Technologies) with a lentivirus expressing cFLIP. Two methods could be 
exploited to test the mechanism of inhibition of IRF7-mediated IFNa expression in 
PBMCs; RT-qCR of multiple ifna genes and an ELISA of IFNa production. I hoped to 
observe that SLE-PBMCs transduced with a cFLIP-expressing lentivirus would produce 
significantly less IFNa compared to control SLE-PBMCs. It would also be exciting to 
see IFNa expression by cFLIP-expressing SLE-PBMCs be comparable to healthy 














1.   Banchereau, J., & Pascual, V. (2006). Type I Interferon in Systemic Lupus 
Erythematosus and Other Autoimmune Diseases. Immunity, 25(3), 383-392. 
doi:10.1016/j.immuni.2006.08.010. 
 
2.   Buskiewicz, I. A., Koenig, A., Roberts, B., Russell, J., Shi, C., Lee, S., . . . Budd, R. 
C. (2014). C-FLIP-Short Reduces Type I Interferon Production and Increases Viremia 
with Coxsackievirus B3. PLoS ONE, 9(5). doi:10.1371/journal.pone.0096156. 
  
3.   Handa, P., Tupper, J. C., Jordan, K. C., & Harlan, J. M. (2011). FLIP (Flice-like 
inhibitory protein) suppresses cytoplasmic double-stranded-RNA-induced apoptosis 
and NF-κB and IRF3-mediated signaling. Cell Communication and Signaling, 9(1), 
16. doi:10.1186/1478-811x-9-16. 
 
4.   Higgs, R., & Jefferies, C. (2008). Targeting IRFs by ubiquitination: regulating 
antiviral responses. Biochemical Society Transactions, 36(3), 453-458. 
doi:10.1042/bst0360453. 
 
5.   Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., . . . Taniguchi, 
T. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune 
responses. Nature, 434(7034), 772-777. doi:10.1038/nature03464. 
 
6.   Miller, R., Han, A., Gates-Tanzer, L., Erdman Jr., J., Shisler, J., Wallig, M., & 
O'Brien Jr., W. (2017). Quantitative Ultrasound and the Pancreas: Demonstration of 
Early Detection Capability. Proceedings of the 2017 IEEE Ultrasonics Symposium 
(pp. 1-4). 
 
7.   Pooran, N., Indaram, A., Singh, P., & Bank, S. (2003). Cytokines (IL-6, IL-8, TNF). 
Journal of Clinical Gastroenterology, 37(3), 263-266. doi:10.1097/00004836-
200309000-00013. 
 
8.   Randall, C. M., Biswas, S., Selen, C. V., & Shisler, J. L. (2013). Inhibition of 
interferon gene activation by death-effector domain-containing proteins from the 
molluscum contagiosum virus. Proceedings of the National Academy of Sciences, 
111(2). doi:10.1073/pnas.1314569111. 
 
9.   Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., . . . 
Chinnaiyan, A. M. (2004). ONCOMINE: A Cancer Microarray Database and 
Integrated Data-Mining Platform. Neoplasia, 6(1), 1-6. doi:10.1016/s1476-
5586(04)80047-2. 
 
10.   Watanabe, K., Koizumi, F., Kurashige, Y., Tsurufuji, S., & Nakagawa, H. (1991). Rat 
CINC, a member of the interleukin-8 family, is a neutrophil-specific chemoattractant 




11.   Willemer, S., Elsässer, H., & Adler, G. (1992). Hormone-Induced Pancreatitis. 
European Surgical Research, 24(1), 29-39. doi:10.1159/000129237. 
 
12.   Zhang, L., & Pagano, J. S. (1997). IRF-7, a new interferon regulatory factor 
associated with Epstein-Barr virus latency. Molecular and Cellular Biology, 17(10), 
5748-5757. doi:10.1128/mcb.17.10.5748. 
	  
 
